Spectrum Pharmaceuticals (SPPI) 10-Q 7 Nov 19 2019 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2019	Oct. 31, 2019
Cover page.
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2019
Document Transition Report	false
Entity File Number	001-35006
Entity Registrant Name	SPECTRUM PHARMACEUTICALS INC
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	93-0979187
Entity Address, Address Line One	11500 South Eastern Avenue
Entity Address, Address Line Two	Suite 240
Entity Address, City or Town	Henderson
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89052
City Area Code	702
Local Phone Number	835-6300
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	SPPI
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		112,973,294
Amendment Flag	false
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Entity Central Index Key	0000831547
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 124,598	$ 157,480
Restricted cash	4,040	0
Marketable securities	123,164	46,508
Accounts receivable, net of allowance for doubtful accounts of $67 and $67, respectively	483	29,873
Other receivables	7,752	3,698
Prepaid expenses and other assets	12,680	7,574
Discontinued operations, current assets (Note 11)	0	5,555
Total current assets	272,717	250,688
Property and equipment, net of accumulated depreciation	8,965	385
Other assets	8,613	7,188
Facility and equipment under lease	3,531	0
Discontinued operations, non-current assets	0	132,625
Total assets	293,826	390,886
Current liabilities:
Accounts payable and other accrued liabilities	39,959	69,460
Accrued payroll and benefits	6,475	9,853
Contract liabilities	1,360	4,850
Discontinued operations, current liabilities (Note 11)	0	2,311
Total current liabilities	47,794	86,474
Deferred tax liabilities	0	1,469
Other long-term liabilities	11,313	5,650
Discontinued operations, non-current liabilities	0	14,031
Total liabilities	59,107	107,624
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.001 par value; 300,000,000 shares authorized; 112,988,706 and 110,525,141 issued and outstanding at September 30, 2019 and December 31, 2018, respectively	113	110
Additional paid-in capital	912,558	886,740
Accumulated other comprehensive loss	(4,531)	(3,702)
Accumulated deficit	(673,421)	(599,886)
Total stockholders’ equity	234,719	283,262
Total liabilities and stockholders’ equity	$ 293,826	$ 390,886

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Allowance for doubtful accounts receivable	$ 67	$ 67
Preferred stock, par value ($ per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (shares)	5,000,000	5,000,000
Preferred stock, shares issued (shares)	0	0
Preferred stock, shares outstanding (shares)	0	0
Common stock, par value ($ per share)	$ 0.001	$ 0.001
Common stock, shares authorized (shares)	300,000,000	300,000,000
Common stock, shares issued (shares)	112,684,387	110,525,141
Common stock, shares outstanding (shares)	112,684,387	110,525,141

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Statement [Abstract]
Revenues (Note 1(b))	$ 0	$ 0	$ 0	$ 0
Operating costs and expenses:
Selling, general and administrative	13,126	13,108	46,308	46,115
Research and development	17,167	15,314	56,035	45,274
Total operating costs and expenses	30,293	28,422	102,343	91,389
Loss from continuing operations before other income (expense) and income taxes	(30,293)	(28,422)	(102,343)	(91,389)
Other income (expense):
Interest income (expense), net	1,521	(12)	4,076	(484)
Other income (expense), net	2,015	(40,880)	(5,547)	17,583
Total other income (expense)	3,536	(40,892)	(1,471)	17,099
Loss from continuing operations before income taxes	(26,757)	(69,314)	(103,814)	(74,290)
Benefit for income taxes from continuing operations	200	142	8,654	839
Loss from continuing operations	(26,557)	(69,172)	(95,160)	(73,451)
Income from discontinued operations, net of income taxes (Note 11)	572	454	21,625	2,659
Net loss	$ (25,985)	$ (68,718)	$ (73,535)	$ (70,792)
Basic and diluted loss per share:
Loss per common share from continuing operations ($ per share)	$ (0.24)	$ (0.66)	$ (0.86)	$ (0.72)
Income per common share from discontinued operations ($ per share)	0.01	0	0.20	0.03
Net loss per common share ($ per share)	$ (0.23)	$ (0.66)	$ (0.67)	$ (0.69)
Weighted average shares outstanding:
Basic (shares)	111,178,880	104,106,295	110,291,090	102,571,850
Diluted (shares)	111,178,880	104,106,295	110,291,090	102,571,850

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive (Loss) Income - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Statement of Comprehensive Income [Abstract]
Net loss	$ (25,985)	$ (68,718)	$ (73,535)	$ (70,792)
Other comprehensive loss:
Unrealized (loss) gain on available-for-sale securities, net of income tax expense of ($2) thousand, $0, and $31 thousand, $0 for the three and nine months ended September 30, 2019 and 2018, respectively.	(7)	0	93	0
Foreign currency translation adjustments	(760)	(254)	(922)	(2,130)
Other comprehensive loss	(767)	(254)	(829)	(2,130)
Total comprehensive loss	$ (26,752)	$ (68,972)	$ (74,364)	$ (72,922)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Comprehensive (Loss) Income (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Statement of Comprehensive Income [Abstract]
Unrealized loss on available-for-sale securities, tax	$ (2)	$ 0	$ 31	$ 0

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	AOCI Attributable to Parent [Member]	Accumulated Deficit [Member]
Beginning Balance, (shares) at Dec. 31, 2017		100,742,735
Beginning Balance at Dec. 31, 2017	$ 351,339	$ 100	$ 837,347	$ 15,999	$ (502,107)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(15,816)				(15,816)
Other comprehensive income (loss), net	393			393
Employee stock-based compensation expense	4,144		4,144
Issuance of common stock to 401(k) plan for employees (shares)		16,834
Issuance of common stock to 401(k) plan for employees	334		334
Issuance of common stock upon exercise of stock options (shares)		5,793,413
Issuance of common stock upon exercise of stock options	41,423	$ 6	41,417
Restricted stock award grants, net of forfeitures (shares)		614,035
Restricted stock award grants, net of forfeitures	0
Retirement of RSAs and shares as part of stock option cashless exercises to satisfy employee tax withholdings (shares)		(3,463,873)
Retirement of RSAs and shares as part of stock option cashless exercises to satisfy employee tax withholdings	(62,544)	$ (3)	(62,541)
Issuance of common stock upon vesting of RSUs (shares)		200,652
Issuance of common stock upon vesting of RSUs	0
Issuance of common stock upon exercise of warrants (shares)		31,602
Issuance of common stock upon exercise of warrants	0
Ending Balance, (shares) at Mar. 31, 2018		103,935,398
Ending Balance at Mar. 31, 2018	324,293	$ 103	820,701	(819)	(495,692)
Beginning Balance, (shares) at Dec. 31, 2017		100,742,735
Beginning Balance at Dec. 31, 2017	351,339	$ 100	837,347	15,999	(502,107)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(70,792)
Ending Balance, (shares) at Sep. 30, 2018		106,060,681
Ending Balance at Sep. 30, 2018	286,779	$ 106	840,681	(3,342)	(550,666)
Beginning Balance, (shares) at Mar. 31, 2018		103,935,398
Beginning Balance at Mar. 31, 2018	324,293	$ 103	820,701	(819)	(495,692)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	13,744				13,744
Other comprehensive income (loss), net	(2,269)			(2,269)
Employee stock-based compensation expense	4,461		4,461
Issuance of common stock to 401(k) plan for employees (shares)		14,736
Issuance of common stock to 401(k) plan for employees	272		272
Issuance of common stock for ESPP (shares)		45,543
Issuance of common stock for ESPP	734		734
Issuance of common stock upon exercise of stock options (shares)		732,694
Issuance of common stock upon exercise of stock options	2,884		2,884
Restricted stock award grants, net of forfeitures (shares)		176,954
Restricted stock award grants, net of forfeitures	0
Issuance of common stock upon exercise of warrants (shares)		225,278
Issuance of common stock upon exercise of warrants	0
Ending Balance, (shares) at Jun. 30, 2018		105,130,603
Ending Balance at Jun. 30, 2018	344,119	$ 103	829,052	(3,088)	(481,948)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(68,718)				(68,718)
Other comprehensive income (loss), net	(254)			(254)
Employee stock-based compensation expense	3,690		3,690
Issuance of common stock to 401(k) plan for employees (shares)		15,010
Issuance of common stock to 401(k) plan for employees	296		296
Issuance of common stock upon exercise of stock options (shares)		428,770
Issuance of common stock upon exercise of stock options	3,042	$ 2	3,040
Restricted stock award grants, net of forfeitures (shares)		(697)
Restricted stock award grants, net of forfeitures	0
Issuance of common stock upon exercise of warrants (shares)		35,695
Issuance of common stock upon exercise of warrants	0
Common stock redeemed on 2018 Convertible Notes (Note 8) (shares)		451,300
Common stock redeemed on 2018 Convertible Notes (Note 8)	4,604	$ 1	4,603
Ending Balance, (shares) at Sep. 30, 2018		106,060,681
Ending Balance at Sep. 30, 2018	286,779	$ 106	840,681	(3,342)	(550,666)
Beginning Balance, (shares) at Dec. 31, 2018		110,525,141
Beginning Balance at Dec. 31, 2018	283,262	$ 110	886,740	(3,702)	(599,886)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(19,155)				(19,155)
Other comprehensive income (loss), net	(390)			(390)
Employee stock-based compensation expense	7,481		7,481
Issuance of common stock to 401(k) plan for employees (shares)		47,347
Issuance of common stock to 401(k) plan for employees	519		519
Issuance of common stock upon exercise of stock options (shares)		146,785
Issuance of common stock upon exercise of stock options	831		831
Restricted stock award grants, net of forfeitures (shares)		259,539
Restricted stock award grants, net of forfeitures	1	$ 1
Issuance of common stock upon vesting of RSUs (shares)		233,760
Issuance of common stock upon vesting of RSUs	0
Ending Balance, (shares) at Mar. 31, 2019		111,212,572
Ending Balance at Mar. 31, 2019	272,549	$ 111	895,571	(4,092)	(619,041)
Beginning Balance, (shares) at Dec. 31, 2018		110,525,141
Beginning Balance at Dec. 31, 2018	283,262	$ 110	886,740	(3,702)	(599,886)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(73,535)
Ending Balance, (shares) at Sep. 30, 2019		112,988,706
Ending Balance at Sep. 30, 2019	234,719	$ 113	912,558	(4,531)	(673,421)
Beginning Balance, (shares) at Mar. 31, 2019		111,212,572
Beginning Balance at Mar. 31, 2019	272,549	$ 111	895,571	(4,092)	(619,041)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(28,395)				(28,395)
Other comprehensive income (loss), net	328			328
Employee stock-based compensation expense	4,814		4,814
Issuance of common stock to 401(k) plan for employees (shares)		24,382
Issuance of common stock to 401(k) plan for employees	205		205
Issuance of common stock for ESPP (shares)		60,606
Issuance of common stock for ESPP	444		444
Issuance of common stock upon exercise of stock options (shares)		504,226
Issuance of common stock upon exercise of stock options	3,023	$ 0	3,023
Restricted stock award grants, net of forfeitures (shares)		651,072
Restricted stock award grants, net of forfeitures	1	$ 1
Issuance of common stock upon vesting of RSUs (shares)		10,000
Issuance of common stock upon vesting of RSUs	0
Issuance of common shares under an at-the-market sales agreement (Note 13) (shares)		221,529
Issuance of common shares under an at-the-market sales agreement (Note 13)	1,814		1,814
Ending Balance, (shares) at Jun. 30, 2019		112,684,387
Ending Balance at Jun. 30, 2019	254,783	$ 112	905,871	(3,764)	(647,436)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(25,985)				(25,985)
Other comprehensive income (loss), net	(767)			(767)
Employee stock-based compensation expense	4,021		4,021
Issuance of common stock to 401(k) plan for employees (shares)		21,454
Issuance of common stock to 401(k) plan for employees	165		165
Issuance of common stock upon exercise of stock options (shares)		364,358
Issuance of common stock upon exercise of stock options	2,499		2,498
Restricted stock award grants, net of forfeitures (shares)		(81,493)
Restricted stock award grants, net of forfeitures	0
Refund of SEC fees in connection with an at-the-market sales agreement for our common shares	3		3
Ending Balance, (shares) at Sep. 30, 2019		112,988,706
Ending Balance at Sep. 30, 2019	$ 234,719	$ 113	$ 912,558	$ (4,531)	$ (673,421)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash Flows From Operating Activities:
Loss from continuing operations	$ (95,160,000)	$ (73,451,000)
Income from discontinued operations, net of income taxes (Note 11)	21,625,000	2,659,000
Net loss	(73,535,000)	(70,792,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,487,000	21,000,000
Stock-based compensation (Note 4)	17,205,000	13,197,000
Recognized gain on Commercial Product Portfolio Transaction (Note 11)	(33,451,000)	0
Non-cash portion of lease expense (Note 9(a))	1,313,000	0
Amortization of discount on investments in debt securities, recorded to interest income (Note 3(a))	(348,000)	0
Income tax recognition on unrealized gain on available-for-sale securities	(31,000)	0
Realized gain on sale of CASI stock (Note 7)	(2,674,000)	0
Unrealized loss (gain) on CASI stock holdings (Note 3(a) and Note 7)	9,745,000	(17,716,000)
Unrealized (gain) loss from transactions denominated in foreign currency	(5,000)	17,000
Change in deferred tax liabilities	(1,469,000)	9,000
Change in fair value of contingent consideration (Note 9(b))	1,478,000	(717,000)
Accretion of discount on 2018 Convertible Notes, recorded to interest expense (Note 8)	0	1,558,000
Amortization of deferred financing costs on 2018 Convertible Notes, recorded to interest expense (Note 8)	0	178,000
Change in cash surrender value of corporate-owned life insurance policy	0	(5,000)
Changes in operating assets and liabilities:
Accounts receivable, net	29,359,000	3,252,000
Other receivables	(4,068,000)	(3,002,000)
Inventories	(2,037,000)	2,862,000
Prepaid expenses and other assets	(5,005,000)	(2,362,000)
Other assets	(1,428,000)	4,890,000
Accounts payable and other accrued obligations	(35,337,000)	(457,000)
Accrued payroll and benefits	(3,378,000)	(1,517,000)
FOLOTYN development liability	(4,000)	(270,000)
Contract liabilities (Note 3(h))	(3,490,000)	0
Other long-term liabilities	2,234,000	(218,000)
Net cash used in operating activities	(103,439,000)	(50,093,000)
Cash Flows From Investing Activities:
Proceeds from Commercial Product Portfolio Transaction (Note 1(b))	158,765,000	0
Proceeds from maturities of investment securities	38,540,000	0
Proceeds from sale of CASI stock (Note 7)	5,074,000	0
Purchase of investment securities available-for-sale (Note 3(a))	(127,584,000)	0
Purchases of property and equipment (Note 3(b))	(8,670,000)	(46,000)
Proceeds from redemption of corporate-owned life insurance policy	0	4,130,000
Net cash provided by investing activities	66,125,000	4,084,000
Cash Flows From Financing Activities:
Proceeds from employees for exercises of stock options	6,355,000	7,843,000
Proceeds from sale of common stock under an at-the-market sales agreement (Note 13)	1,817,000	0
Proceeds from sale of stock under our employee stock purchase plan	444,000	734,000
Proceeds from employees, for our remittance to tax authorities, upon vesting of restricted stock and upon exercises of stock options	0	4,645,000
Payments to tax authorities upon employees' surrender of restricted stock upon vesting and upon exercises of stock options	0	(27,686,000)
Net cash provided by (used in) financing activities	8,616,000	(14,464,000)
Effect of exchange rates on cash, cash equivalents and restricted cash	(144,000)	(309,000)
Net decrease in cash, cash equivalents and restricted cash	(28,842,000)	(60,782,000)
Cash, cash equivalents and restricted cash—beginning of period	157,480,000	227,323,000
Cash, cash equivalents and restricted cash—end of period	128,638,000	166,541,000
Supplemental disclosure of cash flow information:
Cash paid for facility and equipment under operating leases	1,266,000	0
Cash paid for income taxes	38,000	38,000
Cash paid for interest	0	558,000
Noncash investing activities:
Additions of property and equipment that remain in accounts payable (Note 3(b))	$ 300,000	$ 0

Description of Business, Basis

Description of Business, Basis of Presentation, and Operating Segment	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Description of Business, Basis of Presentation, and Operating Segment	DESCRIPTION OF BUSINESS, BASIS OF PRESENTATION, AND OPERATING SEGMENT (a) Description of Business Spectrum Pharmaceuticals, Inc. (“Spectrum”, the “Company”, “we”, “our”, or “us”) is a biopharma company, with a primary strategy comprised of acquiring, developing, and commercializing novel and targeted oncology therapies. Our in-house development organization includes clinical development, regulatory, quality and data management, as well as commercial and marketing capabilities upon product launch. We have two drugs in late-stage development: • Poziotinib, a novel irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer (“NSCLC”) tumors with various mutations; and • ROLONTIS, a novel long-acting granulocyte colony-stimulating (“G-CSF”) for chemotherapy-induced neutropenia. We also have a technology platform that enables the fusion of an interferon-alpha with a monoclonal anti-body: • Anti-CD20-IFNa, the first antibody-interferon fusion molecule directed against CD20 from this platform that is in Phase 1 development for treating relapsed or refractory Non-Hodgkin Lymphoma patients (including diffuse large b-cell lymphoma). Our business strategy is the development of our late-stage assets through commercialization and the sourcing of additional assets that are synergistic with our existing portfolio (through purchase acquisitions, in-licensing transactions, or co-development and marketing arrangements). (b) Basis of Presentation Interim Financial Statements The interim financial data for the three and nine months ended September 30, 2019 and 2018 is unaudited and is not necessarily indicative of our operating results for a full year. In the opinion of our management, the interim data includes normal and recurring adjustments necessary for a fair presentation of our financial results for the three and nine months ended September 30, 2019 and 2018 . Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant to the Securities and Exchange Commission (“SEC”) rules and regulations relating to interim financial statements. The accompanying Condensed Consolidated Financial Statements should be read in conjunction with our audited Consolidated Financial Statements and Notes thereto included within our Annual Report on Form 10-K for the fiscal year ended December 31, 2018 (filed with the SEC on February 28, 2019 ). Discontinued Operations - Sale of our Commercial Product Portfolio On March 1, 2019, we completed the sale of our seven then-commercialized drugs, including FUSILEV, KHAPZORY, FOLOTYN, ZEVALIN , MARQIBO, BELEODAQ, and EVOMELA (the “Commercial Product Portfolio”) to Acrotech Biopharma LLC (“Acrotech”) (the “Commercial Product Portfolio Transaction”). Upon closing we received $158.8 million in an upfront cash payment (of which $4 million was held in escrow until November 5, 2019). We are also entitled to receive up to an aggregate of $140 million upon Acrotech's achievement of certain regulatory (totaling $40 million ) and sales-based milestones (totaling $100 million ) relating to the Commercial Product Portfolio. These Condensed Consolidated Financial Statements are recast for all periods presented to reflect the sale of the assets and liabilities associated with our Commercial Product Portfolio, as well as the corresponding revenue-deriving activities and allocable expenses of this commercial business within “discontinued operations” - see Note 11 . We have presented our face financial statements in general conformity with our historical format, even where presented values are $-0- within continuing operations due to required discontinued operations classification for all periods presented. We believe this format provides increased clarity and comparability with our previously filed financial statements, as well as our expectation that these financial statement captions and associated footnote disclosures will remain relevant to our future business activities. Principles of Consolidation The accompanying Condensed Consolidated Financial Statements have been prepared in accordance with GAAP and with the rules and regulations of the SEC. These financial statements include the financial position, results of operations, and cash flows of Spectrum and its subsidiaries, all of which are wholly-owned. All inter-company accounts and transactions among these legal entities have been eliminated in consolidation. In May 2019, we dissolved Spectrum Pharma Canada Inc., previously consolidated as a “variable interest entity” (as defined under applicable GAAP). (c) Operating Segment We operate one reportable operating segment that is focused exclusively on developing (and eventually marketing) oncology and hematology drug products. For the three and nine months ended September 30, 2019 and 2018 , all of our revenue and operating costs and expenses were solely attributable to these activities (and as applicable, currently and retrospectively classified as “discontinued” within the accompanying Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Operations - see Note 11 ). All of our assets are held in the U.S, except for cash held in certain foreign bank accounts.

Summary of Significant Accounti

Summary of Significant Accounting Policies and Use of Estimates	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies and Use of Estimates	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES The preparation of financial statements in conformity with GAAP requires our management to make informed estimates and assumptions that affect our reported amounts of assets, liabilities, revenues, and expenses. These amounts may materially differ from the amounts ultimately realized and reported due to the inherent uncertainty of any estimate or assumption. On an on-going basis, our management evaluates its most critical estimates and assumptions, including those related to: (i) gross-to-net revenue adjustments; (ii) the timing of revenue recognition; (iii) the collectability of customer accounts; (iv) whether the cost of our inventories can be recovered; (v) the realization of our tax assets and estimates of our tax liabilities; (vi) the fair value of our investments; (vii) the valuation of our stock options and the periodic expense recognition of stock-based compensation; and (viii) the potential outcome of our ongoing or threatened litigation. Our accounting policies and estimates that most significantly impact the presented amounts within these Condensed Consolidated Financial Statements are further described below: (i) Revenue Recognition On March 1, 2019, we completed the Commercial Product Portfolio Transaction -- see Note 1(b) . In accordance with applicable GAAP ( ASC 205-20, Presentation of Financial Statements ), the revenue-deriving activities of our sold commercial operation are separately classified as “discontinued” for all periods presented within the accompanying Condensed Consolidated Statements of Operations -- see Note 11 . Impact of the Adoption of the New Revenue Recognition Standard : ASU No. 2014-09 , Revenue from Contracts with Customers ( “Topic 606” ), became effective for us on January 1, 2018. Our disclosure within the below sections to this footnote reflects our updated accounting policies that are affected by this new standard. We applied the “modified retrospective” transition method for open contracts for the implementation of Topic 606; this resulted in the recognition of an aggregate $4.7 million , net of tax, decrease to our January 1, 2018 “accumulated deficit” on our accompanying Condensed Consolidated Balance Sheets for the cumulative impact of applying this new standard. We made no adjustments to our previously-reported total revenues, as those periods continue to be presented in accordance with our historical accounting practices under Topic 605, Revenue Recognition (“Topic 605”) . Required Elements of Our Revenue Recognition : Revenue from our (a) product sales, (b) out-license arrangements, and (c) service arrangements is recognized under Topic 606 in a manner that reasonably reflects the delivery of our goods and/or services to customers in return for expected consideration and includes the following elements: (1) we ensure that we have an executed contract(s) with our customer that we believe is legally enforceable; (2) we identify the “performance obligations” in the respective contract; (3) we determine the “transaction price” for each performance obligation in the respective contract; (4) we allocate the transaction price to each performance obligation; and (5) we recognize revenue only when we satisfy each performance obligation. These five elements, as applied to each of our revenue categories, are summarized below: (a) Product Sales : We sell our products to pharmaceutical wholesalers/distributors or to our product licensees (i.e., our customers). Our wholesalers/distributors in turn sell our products directly to clinics, hospitals, and private oncology-based practices. Revenue from our product sales is recognized as physical delivery of product occurs (when our customer obtains control of the product), in return for agreed-upon consideration. Our gross product sales (i.e., delivered units multiplied by the contractual price per unit) are reduced by our corresponding gross-to-net (“GTN”) estimates using the “expected value” method, resulting in reported “product sales, net” that reflects the amount we ultimately expect to realize in net cash proceeds, taking into account our current period gross sales and related cash receipts, and the subsequent cash disbursements on these sales that we estimate for the various GTN categories discussed below. These estimates are based upon information received from external sources (such as written or oral information obtained from our customers with respect to their period-end inventory levels and sales to end-users during the period), in combination with management’s informed judgments. Due to the inherent uncertainty of these estimates, the actual amount incurred (of some, or all) of product returns, government chargebacks, prompt pay discounts, commercial rebates, Medicaid rebates, and distribution, data, and GPO administrative fees may be materially above or below the amount estimated, then requiring prospective adjustments to our reported net product sales. These GTN estimate categories (that comprise our GTN liabilities within Note 3(g) ) are each discussed below: Product Returns Allowances : Our customers are contractually permitted to return certain purchased products within the contractual allowable time before/after its applicable expiration date. Returns outside of this aforementioned criteria are not customarily allowed. We estimate expected product returns using our historical return rates. Returned product is typically destroyed since substantially all are due to its imminent expiry and cannot be resold. Government Chargebacks : Our products are subject to pricing limits under certain federal government programs (e.g., Medicare and 340B Drug Pricing Program). Qualifying entities (i.e., end-users) purchase products from our customers at their qualifying discounted price. The chargeback amount we incur represents the difference between our contractual sales price to our customer, and the end-user’s applicable discounted purchase price under the government program. There may be significant lag time between our reported net product sales and our receipt of the corresponding government chargeback claims from our customers. Prompt Pay Discounts : Discounts for prompt payment are estimated at the time of sale, based on our eligible customers’ prompt payment history and the contractual discount percentage. Commercial Rebates : Commercial rebates are based on (i) our estimates of end-user purchases through a group purchasing organization (“GPO”), (ii) the corresponding contractual rebate percentage tier we expect each GPO to achieve, and (iii) our estimates of the impact of any prospective rebate program changes made by us. Medicaid Rebates : Our products are subject to state government-managed Medicaid programs, whereby rebates are issued to participating state governments. These rebates arise when a patient treated with our product is covered under Medicaid, resulting in a discounted price for our product under the applicable Medicaid program. Our Medicaid rebate accrual calculations require us to project the magnitude of our sales, by state, that will be subject to these rebates. There is a significant time lag in our receiving rebate notices from each state (generally several months or longer after our sale is recognized). Our estimates are based on our historical claim levels by state, as supplemented by management’s judgment. Distribution, Data, and GPO Administrative Fees : Distribution, data, and GPO administrative fees are paid to authorized wholesalers/distributors of our products for various commercial services including: contract administration, inventory management, delivery of end-user sales data, and product returns processing. These fees are based on a contractually-determined percentage of our applicable sales. (b) License Fees : Our out-license arrangements allow licensees to market our product(s) in certain territories for a specific term (representing the out-license of “functional intellectual property”). These arrangements may include one or more of the following forms of consideration: (i) upfront license fees, (ii) sales royalties, (iii) sales milestone-achievement fees, and (iv) regulatory milestone-achievement fees. We recognize revenue for each based on the contractual terms that establish our right to collect payment once the performance obligation is achieved, as follows: (1) Upfront License Fees: We determine whether upfront license fees are earned at the time of contract execution (i.e., when rights transfer to the customer) or over the actual (or implied) contractual period of the out-license. As part of this determination, we evaluate whether we have any other requirements to provide substantive services that are inseparable from the performance obligation of the license transfer. Our customers’ “distinct” rights to licensed “functional intellectual property” at the time of contract execution results in concurrent revenue recognition of all upfront license fees (assuming that there are no other performance obligations at contract execution that are inseparable from this license transfer). (2) Royalties : Under the “sales-or-usage-based royalty exception” we recognize revenue in the same period that our licensees complete product sales in their territory for which we are contractually entitled to a percentage-based royalty receipt. (3) Sales Milestones : Under the “sales-or-usage-based royalty exception” we recognize revenue in full within the period that our licensees achieve annual or aggregate product sales levels in their territories for which we are contractually entitled to a specified lump-sum receipt. (4) Regulatory Milestones : Under the terms of the respective out-license, regulatory achievements may either be our responsibility, or that of our licensee. • When our licensee is responsible for the achievement of the regulatory milestone, we recognize revenue in full (for the contractual amount due from our licensee) in the period that the approval occurs (i.e., when the “performance obligation” is satisfied by our customer) under the “most likely amount” method. This revenue recognition remains “constrained” (i.e., not recognized) until regulatory approval occurs, given its inherent uncertainty and the requirement of a significant revenue reversal not being probable if achievement does not occur. At each reporting period, we re-evaluate the probability of milestone achievement and the associated revenue constraint; any resulting adjustments would be recorded on a cumulative catch-up basis, thus reflected in our financial statements in the period of adjustment. • When we are responsible for the achievement of a regulatory milestone, the “relative selling price method” is applied for purposes of allocating the transaction price to our performance obligations. In such case, we consider (i) the extent of our effort to achieve the milestone and/or the enhancement of the value of the delivered item(s) as a result of milestone achievement and (ii) if the milestone payment is reasonable relative to all of the deliverables and payment terms (including other potential milestone consideration) within the arrangement. We have historically assessed the contractual value of these milestones upon their achievement to be identical to the allocation of value of our performance obligations and thus representing the “transaction price” for each milestone at contract inception. We recognize this revenue in the period that the regulatory approval occurs (i.e., when we complete the “performance obligation”) under the “most likely amount” method, and revenue recognition is otherwise “constrained” until regulatory approval occurs, given its inherent uncertainty and the requirement of a significant revenue reversal not being probable if achievement does not occur. At each reporting period, we re-evaluate the probability of milestone achievement and the associated revenue constraint; any resulting adjustments would be recorded on a cumulative catch-up basis, thus reflected in our financial statements in the period of adjustment. (c) Service Revenue : We receive fees under certain arrangements for (i) sales and marketing services, (ii) supply chain services, (iii) research and development services, and (iv) clinical trial management services. Our rights to receive payment for these services may be established by (1) a fixed-fee schedule that covers the term of the arrangement, so long as we meet ongoing performance obligations, (2) our completion of product delivery in our capacity as a procurement agent, (3) the successful completion of a phase of drug development, (4) favorable results from a clinical trial, and/or (5) regulatory approval events. We consider whether revenue associated with these service arrangements is reportable each period, based on our completed services or deliverables (i.e., satisfied “performance obligations”) during the reporting period, and the terms of the arrangement that contractually result in fixed payments due to us. The promised service(s) within these arrangements are distinct and explicitly stated within each contract, and our customer benefits from the separable service(s) delivery/completion. Further, the nature of the promise to our customer as stated within the respective contract is to deliver each named service individually (not a transfer of combined items to which the promised goods or services are inputs), and thus are separable for revenue recognition. (ii) Cash and Cash Equivalents Cash and cash equivalents consist of bank deposits and highly liquid investments with maturities of three months or less from the purchase date. Our restricted cash is currently held in an escrow account as part of our completed Commercial Product Portfolio Transaction (see Note 1(b) ). (iii) Marketable Securities Marketable securities consist of our holdings in equity securities, mutual funds, bank certificates of deposit (“Bank CDs”), government-related debt securities, and corporate debt securities. Since we classify these investments as “available-for-sale” any (1) realized gains (losses) or (2) unrealized gains (losses) on these securities are respectively recognized in (1) “other income (expense), net” on the accompanying Condensed Consolidated Statements of Operations, or recognized in (2) “accumulated other comprehensive loss” as a separate component of stockholder’s equity on the accompanying Condensed Consolidated Statements of Stockholders’ Equity. (iv) Accounts Receivable Our accounts receivable are derived from our product sales and license fees, and do not bear interest. The allowance for doubtful accounts is management’s best estimate of the amount of probable credit losses in our existing accounts receivable. Account balances are charged off against the allowance after appropriate collection efforts are exhausted. (v) Inventories We value our inventory at the lower of (i) the actual cost of its purchase or manufacture, or (ii) its net realizable value. Inventory cost is determined on the first-in, first-out method. We regularly review our inventory quantities in process of manufacture and on hand. When appropriate, we record a provision for obsolete and excess inventory to derive its new cost basis, which takes into account our sales forecast by product and corresponding expiry dates of each product lot. Manufacturing costs of drug products that are pending U.S. Food and Drug Administration (“FDA”) approval are exclusively recognized through “research and development” expense on the accompanying Condensed Consolidated Statements of Operations. (vi) Stock-Based Compensation Stock-based compensation expense for equity awards granted to our employees and members of our Board of Directors is recognized on a straight-line basis over each award’s vesting period. Recognized compensation expense is net of an estimated forfeiture rate, representing the percentage of awards that are expected to be forfeited prior to vesting, though is ultimately adjusted for actual forfeitures. We use the Black-Scholes option pricing model to determine the fair value of stock options (as of the date of grant) that have service conditions for vesting. We use the Monte Carlo valuation model to value equity awards (as of the date of grant) that have combined market conditions and service conditions for vesting. The recognition of stock-based compensation expense and the initial calculation of stock option fair value requires uncertain assumptions, including (a) the pre-vesting forfeiture rate of the award, (b) the expected term that the stock option will remain outstanding, (c) our stock price volatility over the expected term (and that of our designated peer group with respect to certain market-based awards), and (d) the prevailing risk-free interest rate for the period matching the expected term. With regard to (a)-(d) above: we estimate forfeiture rates based on our employees’ overall forfeiture history, which we believe will be representative of future results. We estimate the expected term of stock options granted based on our employees’ historical exercise patterns, which we believe will be representative of their future behavior. We estimate the volatility of our common stock on the date of grant based on the historical volatility of our common stock for a look-back period that corresponds with the expected term. We estimate the risk-free interest rate based upon the U.S. Department of the Treasury yields in effect at award grant, for a period equaling the expected term of the stock option. (vii) Basic and Diluted Net Loss per Share We calculate basic and diluted net loss per share using the weighted average number of common shares outstanding during the periods presented. In periods of a net loss, basic and diluted loss per share are the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include only dilutive stock options, warrants, and other common stock equivalents outstanding during the period. (viii) Income Taxes Deferred tax assets and liabilities are recorded based on the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the financial statements, as well as operating losses and tax credit carry forwards using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain. We have recorded a valuation allowance to reduce our deferred tax assets, because we believe that, based upon a weighting of positive and negative factors, it is more likely than not that these deferred tax assets will not be realized. If/when we were to determine that our deferred tax assets are realizable, an adjustment to the corresponding valuation allowance would increase our net income in the period that such determination was made. In the event that we are assessed interest and/or penalties from taxing authorities that have not been previously accrued, such amounts would be included in “benefit for income taxes from continuing operations” within the accompanying Condensed Consolidated Statements of Operations for the period in which we received the notice. (ix) Research and Development Costs Our research and development costs are expensed as incurred (see Note 9(c) ) or as certain milestone payments become contractually due to our licensors, as triggered by the achievement of clinical or regulatory events. (x) Fair Value Measurements We determine measurement-date fair value based on the proceeds that would be received through the sale of the asset, or that we would pay to settle or transfer the liability, in an orderly transaction between market participants. We utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include the following: Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date. Level 2: Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public. Level 3:

Balance Sheet Account Detail

Balance Sheet Account Detail	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Account Detail	BALANCE SHEET ACCOUNT DETAIL The composition of selected financial statement captions that comprise the accompanying Condensed Consolidated Balance Sheets are summarized below: (a) Cash and Cash Equivalents and Marketable Securities As of September 30, 2019 and December 31, 2018 , our “cash and cash equivalents” were held with major financial institutions. As of September 30, 2019 , our “marketable securities” include our equity holdings in CASI Pharmaceuticals, Inc. (“CASI”), mutual funds, government-related debt securities, corporate debt securities, and bank certificates of deposits (“bank CDs”). We maintain cash balances with select financial institutions. The Federal Deposit Insurance Corporation (FDIC) and other third parties insure a fraction of these deposits. Accordingly, these cash deposits are not insured against the possibility of a substantial or complete loss of principal and are inherently subject to the credit risk of the corresponding financial institution. Our investment policy requires that purchased investments may only be in highly-rated and liquid financial instruments and limits our holdings of any single issuer (excluding any debt or equity securities that may be received from our strategic partners in connection with licensing arrangements, as discussed in Note 7 ). The carrying amount of our equity securities, money market funds, and Bank CDs approximates their fair value (utilizing “ Level 1” or “ Level 2” inputs – see Note 2(x) ) because of our ability to immediately convert these instruments into cash with minimal expected change in value. As of September 30, 2019 , our held securities that remain in an unrealized loss position for less than one year were insignificant and are presented in the table below. The following is a summary of our presented composition of “cash and cash equivalents” and “marketable securities”: Historical or Amortized Cost Foreign Currency Translation Unrealized Cash and Cash Marketable Securities September 30, 2019 Equity securities* (see Note 7 ) $ 8,710 $ (5,285 ) $ 30,134 $ — $ 33,559 $ — $ 33,559 Money market funds 89,041 — — — 89,041 89,041 — Government-related debt securities** 60,087 — 55 — 60,142 — 60,142 Corporate debt securities** 44,182 — 47 (5 ) 44,224 20,913 23,311 Bank deposits 14,644 — — — 14,644 14,644 — Bank CDs 6,126 — 26 — 6,152 — 6,152 Total cash and cash equivalents and marketable securities $ 222,790 $ (5,285 ) $ 30,262 $ (5 ) $ 247,762 $ 124,598 $ 123,164 December 31, 2018 Equity securities* (see Note 7 ) $ 8,710 $ (2,168 ) $ 39,880 $ — $ 46,422 $ — $ 46,422 Money market funds 142,745 — — — 142,745 142,745 — Bank deposits 14,735 — — — 14,735 14,735 — Bank CDs 86 — — — 86 — 86 Total cash and cash equivalents and marketable securities $ 166,276 $ (2,168 ) $ 39,880 $ — $ 203,988 $ 157,480 $ 46,508 * Beginning January 1, 2018, under the requirements of ASU 2016-01, Recognition and Measurement of Financial Assets and Liabilities , the unrealized gain (loss) on our CASI equity securities are recognized as an increase (decrease) to “other income (expense), net” on the Condensed Consolidated Statements of Operations (rather than through “other comprehensive loss”) on the Condensed Consolidated Statements of Comprehensive Loss). Our adoption of ASU 2016-01 on January 1, 2018 resulted in a $17.2 million cumulative-effect adjustment, net of income tax, reported as a decrease to “accumulated other comprehensive loss” and a decrease to “accumulated deficit” on the accompanying Condensed Consolidated Balance Sheets. Our unrealized gains (losses) on these equity securities for the three and nine months ended September 30, 2019 was $2.0 million and ($9.7) million , respectively, as reported in “other income (expense), net” on the accompanying Condensed Consolidated Statements of Operations. ** Beginning in the second quarter of 2019, we purchased certain government and corporate debt securities. We have classified these as “available-for-sale” since we may redeem or sell these investments before their stated maturity to fund our operations. Under the requirements of ASC 320, Investments - Debt and Equity Securities: (i) we recorded these securities at initial “book value” and then amortize, through maturity, the determined “discount” or “premium” within “interest income” on the accompanying Condensed Consolidated Statements of Operations, and (ii) we recognize the “unrealized gains (loss)” of these securities (i.e., fair value versus amortized book value) as a separate component of “other comprehensive loss” on the accompanying Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2019 . (b) Property and Equipment, net of Accumulated Depreciation “Property and equipment, net of accumulated depreciation” consists of the following: September 30, 2019 December 31, 2018 Manufacturing equipment* $ 7,601 $ — Computer hardware and software 3,589 3,079 Laboratory equipment 669 635 Leasehold improvements 3,389 2,957 Office furniture 335 212 Property and equipment, at cost 15,583 6,883 (Less): Accumulated depreciation (6,618 ) (6,498 ) Property and equipment, net of accumulated depreciation $ 8,965 $ 385 * This represents owned ROLONTIS production equipment on location at our contract manufacturer. Depreciation expense (included within “total operating costs and expenses” in the accompanying Condensed Consolidated Statements of Operations) for the three and nine months ended September 30, 2019 and 2018 was $0.1 million , $0.1 million , $0.2 million , and $0.2 million , respectively. (c) Prepaid Expenses and Other Assets “Prepaid expenses and other assets” consists of the following: September 30, 2019 December 31, 2018 Vendor deposits $ 12,628 $ 6,792 Prepaid insurance 52 782 Prepaid expenses and other assets $ 12,680 $ 7,574 (d) Other Receivables “Other receivables” consists of the following: September 30, 2019 December 31, 2018 Insurance receivable* $ 4,781 $ 206 Other miscellaneous receivables (including Medicaid rebate credits and royalty receivables from licensees) 1,549 1,189 Secured promissory note (see Note 7 ) — 1,525 Income tax receivable - current portion 632 643 Interest receivable from marketable securities (see Note 3(a) ) 627 — Reimbursements due from development partners for incurred research and development expenses 163 135 Other receivables $ 7,752 $ 3,698 * This insurance receivable balance represents our incurred legal fees and pending and completed settlements that are expected to be reimbursed by our insurance carriers. (e) Other Assets “Other assets” consists of the following: September 30, 2019 December 31, 2018 Key employee life insurance – cash surrender value associated with deferred compensation plan ( Note 9(f) ) $ 7,882 $ 6,274 Income tax receivable - non-current portion* 668 668 Research & development supplies and other 63 246 Other assets $ 8,613 $ 7,188 * This value represents the non-current portion of refundable alternative minimum tax payments made that are expected to be received over the next few years (see Note 10 ). (f) Facility and Equipment Under Lease “Facility and equipment under lease” consists of the following : September 30, 2019 December 31, 2018 Office and research facilities $ 3,092 $ — Office equipment 439 — Facility and equipment under lease ( Note 9(a) ) $ 3,531 $ — (g) Accounts Payable and Other Accrued Liabilities “Accounts payable and other accrued liabilities” consists of the following : September 30, 2019 December 31, 2018 Trade accounts payable and other $ 30,321 $ 44,919 Lease liability - current portion ( Note 9(a) ) 326 — Accrued commercial/Medicaid rebates 3,058 8,371 Accrued product royalty due to licensors 58 4,337 Allowance for product returns 4,985 5,171 Accrued data and distribution fees 832 3,248 Accrued GPO administrative fees 11 296 Accrued inventory management fees 368 388 Allowance for government chargebacks — 2,730 Accounts payable and other accrued liabilities $ 39,959 $ 69,460 Amounts presented within “accounts payable and other accrued liabilities” in the accompanying Condensed Consolidated Balance Sheets for our categories of GTN estimates (see Note 2(i) ) were as follows: Commercial/Medicaid Rebates and Government Chargebacks Distribution, Data, Inventory and Product Return Allowances Balance as of December 31, 2017 $ 10,358 $ 5,727 $ 4,045 Add: GTN accruals recorded for product sales 65,751 13,962 1,700 (Less): Payments made and credits against GTN accruals (65,008 ) (15,757 ) (574 ) Balance as of December 31, 2018 $ 11,101 $ 3,932 $ 5,171 Add: GTN accruals recorded for product sales 7,252 1,197 167 (Less): Payments made and credits against GTN accruals (15,295 ) (3,918 ) (353 ) Balance as of September 30, 2019 $ 3,058 $ 1,211 $ 4,985 (h) Contract Liabilities “Contract liabilities” consists of the following: September 30, 2019 December 31, 2018 Customer deposit for EVOMELA supply in China territory ( see Note 7 ) $ 1,360 $ 4,850 Contract liabilities $ 1,360 $ 4,850 (i) Other Long-Term Liabilities “Other long-term liabilities” consists of the following: September 30, 2019 December 31, 2018 Deferred compensation liability ( Note 9(f) ) $ 7,708 $ 5,474 Lease liability - non-current portion ( Note 9(a) ) 3,429 — Other tax liabilities 176 176 Other long-term liabilities $ 11,313 $ 5,650

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	STOCK-BASED COMPENSATION We report our stock-based compensation expense (inclusive of our incentive stock plan, employee stock purchase plan, and 401(k) contribution matching program) in the accompanying Condensed Consolidated Statements of Operations, based on the assigned department of the recipient. Stock-based compensation expense, included within “total operating costs and expenses” for the three and nine months ended September 30, 2019 and 2018 , was as follows: Three Months Ended Nine Months Ended 2019 2018 2019 2018 Selling, general and administrative $ 3,156 $ 1,902 $ 10,550 $ 6,686 Research and development 1,030 603 3,251 1,884 Total stock-based compensation $ 4,186 $ 2,505 $ 13,801 $ 8,570

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Net Loss Per Share	NET LOSS PER SHARE Net loss per share was computed by dividing net loss by the weighted average number of common shares outstanding for the three and nine months ended September 30, 2019 and 2018 : Three Months Ended Nine Months Ended 2019 2018 2019 2018 Weighted average shares outstanding - basic and diluted 111,178,880 104,106,295 110,291,090 102,571,850 Net loss $ (25,985 ) $ (68,718 ) $ (73,535 ) $ (70,792 ) Net loss per share – basic and diluted $ (0.23 ) $ (0.66 ) $ (0.67 ) $ (0.69 ) The below outstanding securities for the three and nine months ended September 30, 2019 and 2018 , were excluded from the above calculation of net loss because their impact under the “treasury stock method” and “if-converted method” would have been anti-dilutive due to our net loss per share in each respective period, as summarized below. Three Months Ended Nine Months Ended 2019 2018 2019 2018 Common stock options issued 635,175 3,702,092 1,198,358 4,175,866 Restricted stock awards issued 1,695,123 1,751,876 1,695,123 1,751,876 Restricted stock units issued 385,919 245,214 385,919 245,214 Employee stock purchase plan shares pending issuance 30,823 21,033 30,823 21,033 2013 Convertible Notes outstanding- if converted into common shares — 3,403,659 — 3,403,659 Total 2,747,040 9,123,874 3,310,223 9,597,648

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS The table below summarizes certain asset and liability fair values that are included within our accompanying Condensed Consolidated Balance Sheets, and their designations among the three fair value measurement categories (see Note 2(x)) : September 30, 2019 Level 1 Level 2 Level 3 Total Assets: Equity securities ( Note 7 ) $ 33,559 $ — $ — $ 33,559 Bank CDs — 6,152 — 6,152 Mutual funds — 29 — 29 Restricted cash 4,040 — — 4,040 Deferred compensation investments (life insurance cash surrender value ( Note 3(e) ) — 7,882 — 7,882 * Money market funds 89,041 — — 89,041 Government-related debt securities 37,448 22,694 — 60,142 Corporate debt securities — 44,224 — 44,224 $ 164,088 $ 80,981 $ — $ 245,069 Liabilities: Deferred compensation liability ( Note 9(f) ) $ — $ 7,848 $ — $ 7,848 * $ — $ 7,848 $ — $ 7,848 December 31, 2018 Level 1 Level 2 Level 3 Total Assets: Bank CDs $ — $ 86 $ — $ 86 Money market funds — 142,745 — 142,745 Equity securities ( Note 7 ) 46,422 — — 46,422 Mutual funds — 78 — 78 Deferred compensation investments (life insurance cash surrender value ( Note 3(e) ) — 6,274 — 6,274 * $ 46,422 $ 149,183 $ — $ 195,605 Liabilities: Deferred compensation liability ( Note 9(f) ) $ — $ 6,167 $ — $ 6,167 * $ — $ 6,167 $ — $ 6,167 * The reported amount of “deferred compensation investments” is based on the cash surrender value of life insurance policies of named current and former employees at each period-end. The reported amount of “deferred executive compensation liability” is based on the period-end market value of mutual fund investments selected by employee participants of the deferred compensation plan. We did not have any transfers between “Level 1” and “Level 2” (see Note 2(x) ) measurement categories for any periods presented except for “money market funds” included within Level 1 as of September 30, 2019 that were presented within Level 2 as of December 31, 2018 . We believe this change is appropriate since these money market funds have quoted daily prices in active markets that are publicly accessible.

Casi Holdings and Evomela Suppl

Casi Holdings and Evomela Supply Contract	9 Months Ended
	Sep. 30, 2019
Other Commitments [Abstract]
Casi Holdings and Evomela Supply Contract	CASI HOLDINGS AND EVOMELA SUPPLY CONTRACT Overview of CASI Transaction In 2014, we executed three perpetual out-license agreements for our former products ZEVALIN, MARQIBO, and EVOMELA (“CASI Out-Licensed Products”) with CASI, a publicly-traded biopharmaceutical company (NASDAQ: CASI) with a primary focus on the China market (collectively, the “CASI Out-License”). Under the CASI Out-License, we received CASI common stock and a secured promissory note and CASI gained the exclusive rights to distribute the CASI Out-Licensed Products in greater China (which includes Taiwan, Hong Kong, and Macau). On March 1, 2019, we completed the Commercial Product Portfolio Transaction (see Note 1(b) ) and substantially all of the contractual rights and obligations associated with these products, including the CASI Out-License, were transferred to Acrotech at closing. However, on an interim basis we retained our original supply agreement with CASI for EVOMELA. Corresponding revenue for shipped product has been recognized within discontinued operations “product sales, net” (see Note 11 ). With our fulfillment of this order in October 2019, we will not have any further involvement with this arrangement. Our Ownership in CASI at September 30, 2019 Under certain conditions that expired in December 2017, we exercised our rights during 2016 and 2017 to purchase additional shares of CASI common stock at par value in order to maintain our post-investment ownership percentage. Our aggregate holding of 10.0 million CASI common shares as of September 30, 2019 represented an approximate 10.4% ownership with a fair market value of $33.6 million (see Note 3(a) ) . In April 2019, we completed the sale of 1.5 million shares and recognized a $2.7 million gain within “other income (expense), net” within the accompanying Condensed Consolidated Statements of Operations for the nine months ended September 30, 2019 .

Convertible Senior Notes and In

Convertible Senior Notes and Interest Expense	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Convertible Senior Notes and Interest Expense	CONVERTIBLE SENIOR NOTES AND INTEREST EXPENSE Overview of 2013 Convertible Notes On December 17, 2013, we entered into an agreement for the sale of $120 million aggregate principal amount of 2.75% Convertible Senior Notes (the “2013 Convertible Notes”). During 2016 and 2017, we completed certain open market purchases to retire $79.5 million in principal amount of the 2013 Convertible Notes. Maturity of the 2013 Convertible Notes occurred on December 15, 2018 and substantially all remaining notes were converted into our common stock at a rate of 95 shares per $1,000 principal units. Components of Interest Expense on 2013 Convertible Notes The following table sets forth the components of interest expense recognized in the accompanying Condensed Consolidated Statements of Operations for the 2013 Convertible Notes. Three Months Ended September 30, 2018 Nine Months Ended September 30, 2018 Stated coupon interest expense $ 246 $ 798 Amortization of debt issuance costs 56 178 Accretion of debt discount 491 1,558 Total interest expense $ 793 $ 2,534 Effective interest rate 8.4 % 8.4 %

Financial Commitments & Conting

Financial Commitments & Contingencies and Key License Agreements	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Financial Commitments & Contingencies and Key License Agreements	FINANCIAL COMMITMENTS & CONTINGENCIES AND KEY LICENSE AGREEMENTS (a) Facility and Equipment Leases Overview In the ordinary course of our business, we enter into leases with unaffiliated parties for the use of (i) office and research facilities and (ii) office equipment. Our current leases have remaining terms ranging from less than one year to five years and none include any residual value guarantees, restrictive covenants, term extensions, or early-termination options. Our facility leases have minimum annual rents, payable monthly, and some carry fixed annual rent increases. Under some of these arrangements, real estate taxes, insurance, certain operating expenses, and common area maintenance are reimbursable to the lessor. These amounts are expensed as incurred, as they are variable in nature and therefore excluded from the measurement of our reported lease asset and liability discussed below. During the three and nine months ended September 30, 2019 and 2018 , we had no sublease arrangements with us as lessor. Adoption of the New Lease Accounting Standard Beginning January 1, 2019, we adopted ASU 2016-02, Leases (“ Topic 842 ”). Under this new lease accounting standard, we recognized a "right-of-use asset" and "lease liability" on our accompanying Condensed Consolidated Balance Sheets for all leases (except for any lease with an original term of less than 12 months). We elected the “optional transition method” upon adoption of Topic 842 and the available practical expedients. Accordingly, we did not reassess (i) lease classification (as either operating or financing) or (ii) initial direct costs for existing leases. This reported asset and liability, respectively, represents (i) the economic benefit of our use of leased facilities and equipment and (ii) the present-value of our contractual minimum lease payments, applying our estimated incremental borrowing rate as of the lease commencement date (since an implicit interest rate is not readily determinable in any of our leases). We recorded $4.2 million to our January 1, 2019 balance sheet for both (i) our right-of-use asset within “facility and equipment under lease” and (ii) our lease liability within “accounts payable and accrued liabilities” and “other long-term liabilities.” The recorded asset and liability associated with each lease is amortized over the respective lease term using the “effective interest rate” method. We elected to (1) not separate “lease components” from “non-lease components” in our measurement of minimum payments for (i) facility leases and (ii) office equipment leases and (2) not recognize a lease asset and liability for a term of 12 months or less. We recognize lease expense on a straight-line basis over the expected term of these operating leases, as reported within “selling, general and administrative” expense on the accompanying Condensed Consolidated Statements of Operations. For the three and nine months ended September 30, 2019 and 2018 , this expense aggregated $0.5 million , $0.5 million , $1.6 million and $1.3 million , respectively. Financial Reporting Captions The below table summarizes these lease asset and liability accounts presented on our accompanying Condensed Consolidated Balance Sheets: Operating Leases* Condensed Consolidated Balance Sheet Caption Balance as of September 30, 2019 Operating lease right-of-use assets - non-current Facility and equipment under lease $ 3,531 Operating lease liabilities - current Accounts payable and other accrued liabilities $ 326 Operating lease liabilities - non-current Other long-term liabilities 3,429 Total operating lease liabilities $ 3,755 * As of September 30, 2019 , we have no “finance leases” as defined in Topic 842 . Components of Lease Expense We recognize lease expense on a straight-line basis over the term of our operating leases, as reported within “selling, general and administrative” expense on the accompanying Condensed Consolidated Statements of Operations. The components of our aggregate lease expense is summarized below: Three Months Ended September 30, 2019 Nine Months Ended September 30, 2019 Operating lease cost $ 351 $ 1,202 Variable lease cost 108 323 Short-term lease cost 20 59 Total lease cost $ 479 $ 1,584 Weighted Average Remaining Lease Term and Applied Discount Rate Weighted Average Remaining Lease Term Weighted Average Discount Rate Operating leases as of September 30, 2019 3 years 7.8% Future Contractual Lease Payments as of September 30, 2019 The below table summarizes our (i) minimum lease payments over the next five years, (ii) lease arrangement implied interest, and (iii) present value of future lease payments: Operating Leases - future payments September 30, 2019 2019 (remaining) $ 383 2020 1,441 2021 1,465 2022 828 2023 87 Total future lease payments, undiscounted $ 4,204 (Less): Implied interest (449 ) Present value of operating lease payments $ 3,755 On October 9, 2019, we entered into an operating lease agreement for office space in the Greater Boston area. Our undiscounted payment obligations are $0.8 million for the November 2019 through May 2021 term of this lease. Contractual Lease Payments as of December 31, 2018 The below is required tabular disclosure for comparative purposes with our current period-end balance sheet date above: Operating Leases - future payments December 31, 2018 2019 $ 1,486 2020 1,441 2021 1,465 2022 828 2023 and thereafter 87 $ 5,308 (b) In/Out Licensing Agreements and Co-Development Arrangements Overview The in-license agreements for our development-stage drug products provide us with territory-specific rights to their manufacture and distribution (including further sub-licensing/out-licensing rights). We are generally responsible for all related clinical development costs, patent filings and maintenance costs, marketing costs, and liability insurance costs. We are also obligated to make specified milestone payments to our licensors upon the achievement of certain regulatory and sales milestones, and to pay royalties based on our net sales of all in-licensed products. We also may enter into out-license agreements for territory-specific rights to these drug products which include one or more of: upfront license fees, royalties from our licensees’ sales, and/or milestone payments based on our licensees’ sales or regulatory achievements. For certain drug products, we may enter into cost-sharing arrangements with licensees and licensors. Impact of Commercial Product Portfolio Transaction on Rights and Obligations Associated with the Product Portfolio On March 1, 2019, we completed the Commercial Product Portfolio Transaction and substantially all of the contractual rights and obligations associated with the Commercial Product Portfolio that were previously disclosed in Note 17(b) to our 2018 Annual Report on Form 10-K were transferred to Acrotech at the closing of the Commercial Product Portfolio Transaction. However, under the terms of this transaction we retained our trade “accounts receivable” and GTN liabilities included within “accounts payable and other accrued liabilities” (see Note 3(g) ) associated with our product sales made on and prior to February 28, 2019. Accordingly, these Condensed Consolidated Financial Statements are recast for all periods presented to reflect the sale of the assets and liabilities associated with our Product Portfolio, as well as the corresponding revenue-deriving activities and allocable expenses of this commercial business within “discontinued operations” - see Notes 1 and 11 . The most significant remaining agreements associated with our continuing operations are listed below, along with the key financial terms and our corresponding accounting and reporting conventions for each: (i) ROLONTIS: Co-Development and Commercialization Agreement with Hanmi Pharmaceutical Co. Ltd In October 2014, we exercised our option under a License Option and Research Collaboration Agreement dated January 2012 (as amended) with Hanmi Pharmaceutical Co. Ltd., or Hanmi, for ROLONTIS (formerly referred to as “LAPS-G-CSF” or “SPI-2012”), a drug based on Hanmi’s proprietary LAPSCOVERY™ technology for the treatment of chemotherapy induced neutropenia. Under the terms of this agreement, as amended, we have primary financial responsibility for the ROLONTIS development plan and hold its worldwide rights (except for Korea, China, and Japan). We are contractually obligated to pay Hanmi tiered royalties that range from the low double-digits to mid-teen on our net sales of ROLONTIS. In January 2016, the first patient was dosed with ROLONTIS as part of our clinical trial. This triggered our contractual milestone payment to Hanmi, and in April 2016, we issued 318,750 shares of our common stock to Hanmi. We are responsible for further contractual payments upon the achievement, at our expense, of a regulatory milestone (which will generate a payment of $10 million to Hanmi), and sales milestone payments of up to $120 million per calendar year based on our net sales of ROLONTIS. Depending on the nature of the milestone achievement we will either (a) capitalize the value to “intangible assets” in the Consolidated Balance Sheets or (b) recognize the value within “research and development” or “cost of product sales” within the Consolidated Statements of Operations. The corresponding payment due to this licensor will be recognized in the Consolidated Balance Sheets within “accounts payable and other accrued liabilities” in the earliest period that we determine the respective milestone achievement is probable or occurs. (ii) Poziotinib: In-License Agreement with Hanmi and Exclusive Patent and Technology License Agreement with MD Anderson In February 2015, we executed an in-license agreement with Hanmi for poziotinib, a pan-HER inhibitor in Phase 2 clinical trials, (which has also shown single agent activity in the treatment of various cancer types during Phase 1 studies, including breast, gastric, colorectal, and lung cancers) and made an upfront payment for these rights. Under the terms of this agreement, we received the exclusive rights to commercialize poziotinib, excluding Korea and China. Hanmi and its development partners are fully responsible for the completion of on-going Phase 2 trials in Korea. We are financially responsible for all other clinical studies. We are contractually obligated to make payments to Hanmi upon the achievement, at our expense, of various regulatory milestones aggregating $33 million and annual net sales milestones of up to $325 million . We are also contractually obligated to pay Hanmi royalties in the low to mid-teen digits on our net sales of poziotinib, potentially reduced by royalties due to other third parties. Depending on the nature of the milestone achievement we will either (a) capitalize the value to “intangible assets” in the Consolidated Balance Sheets or (b) recognize the value within “research and development” or “cost of product sales” within the Consolidated Statements of Operations. The corresponding payment due to this licensor will be recognized in the Consolidated Balance Sheets within “other accrued liabilities” in the earliest period that we determine the respective milestone achievement is probable or occurs. In April 2018, we executed an exclusive patent and technology agreement for the use of poziotinib in treating patients with EGFR and HER2 exon 20 mutations in cancer and HER2 exon 19 mutations in cancer with The University of Texas M.D. Anderson Cancer Center (“MD Anderson”) that had discovered its use in treating these patient-types (“Exon 19/20 Patients”) and made an upfront payment for these rights. We are contractually obligated to pay nominal fixed annual license maintenance fees to MD Anderson and pay additional fees upon the achievement, at our expense, of various regulatory milestones aggregating $9 million and sales milestones of up to $30 million . We are also contractually obligated to pay MD Anderson royalties in the low single-digits on our net sales of poziotinib. Depending on the nature of the milestone achievement we will either (a) capitalize the value to “intangible assets” in the Consolidated Balance Sheets or (b) recognize the value within “research and development” or “cost of product sales” within the Consolidated Statements of Operations. The corresponding payment due to this licensor will be recognized in the Consolidated Balance Sheets within “accounts payable and other accrued liabilities” in the earliest period that we determine the respective milestone achievement is probable or occurs. (iii) In-License Agreement with ImmunGene for FIT Drug Delivery Platform and Two Early-Stage Drugs In April 2019, we executed an asset transfer, license, and sublicense agreement with ImmunGene, Inc. (“ImmunGene”) for an exclusive license for the intellectual property related to the Focused Interferon Therapeutics (“FIT”) drug delivery platform and two early-stage drugs: (i) Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase 1 development for treating relapsed or refractory non-Hodgkin lymphoma, including diffuse large b-cell lymphoma patients, representing a considerable unmet medical need and (ii) an antibody-interferon fusion molecule directed against GRP94, a target for which currently there are no existing approved therapies that has the potential for treating both solid and hematologic malignancies. We made upfront payments aggregating $2.8 million to ImmunGene and to several other third parties, all of which were recorded within “research and development” expense within our accompanying Condensed Consolidated Statements of Operations for the nine months ended September 30, 2019 . We will make further payments to ImmunGene upon our achievement, at our expense, of various regulatory milestones that aggregate $26.1 million , plus an additional $5 million milestone payment for each new indication (beyond those described above) approved for either drug in the U.S., Europe, or Japan. Our contractual royalties to ImmunGene are in the high-single digits on our net sales of each drug, potentially reduced by our royalties due to other third parties. We are also contractually obligated to pay nominal fixed annual license maintenance fees to two FIT platform licensors. Depending on the nature of the milestone achievement we will either (a) capitalize the value to “intangible assets” in the Consolidated Balance Sheets or (b) recognize the value within “research and development” or “cost of product sales” within the Consolidated Statements of Operations. The corresponding payment due to this licensor will be recognized in the Consolidated Balance Sheets within “accounts payable and other accrued liabilities” in the earliest period that we determine the respective milestone achievement is probable or occurs. (c) Service Agreements for Research and Development Activities We have entered into various contracts with numerous third party service providers for the execution of our research and development initiatives (to which we assign discreet project codes in order to compile and monitor such expenses). These vendors include raw material suppliers and contract manufacturers for drug products not yet FDA approved, clinical trial sites, clinical research organizations, and data monitoring centers, among others. The financial terms of these agreements are varied and generally obligate us to pay in stages, depending on the achievement of certain events specified in the agreements - such as contract execution, progress of service completion, delivery of drug supply, and the dosing of patients in clinical studies. We recognize these “research and development” expenses and corresponding “accounts payable and other accrued liabilities” in the accompanying financial statements based on estimates of our vendors’ progress of performed services, patient enrollments and dosing, completion of clinical studies, and other events. Should we decide to discontinue and/or slow-down the work on any project, the associated costs for those projects would typically be limited to the extent of the work completed, as we are generally able to terminate these contracts with adequate notice. (d) Supply and Service Agreements Associated with Product Production We have various product supply agreements and/or have issued vendor purchase orders that obligate us to agreed-upon raw material purchases from certain vendors. We also have certain drug production service agreements with select contract manufacturers that obligate us to service fees during the contractual period. These collective commitments do not exceed our planned commercial requirements; the corresponding contracted prices do not exceed their current fair market values. (e) Employment Agreements We entered into revised employment agreements with each of our named executive officers (chief executive officer, chief operating officer, chief financial officer, chief legal officer, and chief medical officer) in April/June 2018 and June 2019, which supersede any prior Change in Control Severance Agreements with such individuals. These agreements provide for the payment of certain benefits to each executive upon his separation of employment under specified circumstances. These arrangements are designed to encourage each to act in the best interests of our stockholders at all times during the course of a change in control event or other significant transaction. (f) Deferred Compensation Plan The Spectrum Pharmaceuticals, Inc. Deferred Compensation Plan (the “DC Plan”) is administered by the Compensation Committee of our Board of Directors and is intended to comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended. The DC Plan is maintained to provide special benefits for a select group of our employees (the “DC Participants”). DC Participants make annual elections to defer a portion of their eligible cash compensation which is then placed into their DC Plan accounts. We match a fixed percentage of these deferrals, and may make additional discretionary contributions. At September 30, 2019 and December 31, 2018 , the aggregate value of this DC Plan liability was $7.8 million and $6.2 million , respectively, and is included within “accounts payable and other accrued liabilities” and “other long-term liabilities” in the accompanying Condensed Consolidated Balance Sheets. (g) Litigation We are involved from time-to-time with various legal matters arising in the ordinary course of business. These claims and legal proceedings are of a nature we believe are normal and incidental to a pharmaceutical business, and may include product liability, intellectual property, employment matters, and other general claims. We may also be subject to derivative lawsuits from time to time. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are assessed at least quarterly and adjusted to reflect the impact of any settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. Although the ultimate resolution of these various matters cannot be determined at this time, we do not believe that such matters, individually or in the aggregate, will have a material adverse effect on our consolidated results of operations, cash flows, or financial condition. Stockholder Litigation Olutayo Ayeni v. Spectrum Pharmaceuticals, Inc., et al. (Filed September 21, 2016 in the United States District Court, Central District of California; Case No. 2:16-cv-07074) (the “Ayeni Action”) and Glen Hartsock v. Spectrum Pharmaceuticals, Inc., et al. (Filed September 28, 2016 in the United States District Court, District Court of Nevada Case; No. 2:16-cv-02279-RFB-GWF) (the “Hartsock Action”). On November 15, 2016, the Ayeni Action was transferred to the United States District Court for the District of Nevada. The parties have stipulated to a consolidation of the Ayeni Action with the Hartsock Action. These class action lawsuits allege that we and certain of our executive officers made false or misleading statements and failed to disclose material facts about our business and the prospects of approval for our New Drug Application to the FDA for QAPZOLA in violation of Section 10(b) (and Rule 10b-5 promulgated thereunder) and 20(a) of the Securities Exchange Act of 1934, as amended. On July 23, 2019, we entered into a memorandum of understanding with these plaintiffs for a collective settlement that is pending court approval. The value of this proposed settlement is included within “other receivables” (see Note 3(d) ) and “accounts payable and other accrued liabilities” on the accompanying Condensed Consolidated Balance Sheet as of September 30, 2019 .

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES We apply an estimated annual effective tax rate (“ETR”) approach for calculating a tax provision for interim periods, as required under GAAP. We recorded a benefit for income taxes from continuing operations of $8.7 million and $0.8 million for the nine months ended September 30, 2019 and 2018 , respectively, in the Condensed Consolidated Statements of Operations. Our ETR differs from the U.S. federal statutory tax rate of 21% primarily as a result of nondeductible expenses and the impact of the valuation allowance on our deferred tax assets. Our provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. A valuation allowance is established when it is more likely than not the future realization of all or some of the deferred tax assets will not be achieved. The evaluation of the need for a valuation allowance is performed on a jurisdiction by jurisdiction basis, and includes a review of all available positive and negative evidence. We recognize the impact of a tax position in our financial statements only if that position is more likely than not to be sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected in income tax expense. The intraperiod tax allocation guidance requires that we allocate income taxes between continuing operations and other categories of earnings. When we have a year-to-date pre-tax loss from continuing operations and year-to-date pre-tax income in discontinued operations, applicable GAAP ( ASC 740-20-45-7 ) requires that we allocate the income tax provision to other categories of earnings (including discontinued operations), and then record a related tax benefit in continuing operations. For the nine months ended September 30, 2019 and 2018 , we recognized net income from discontinued operations while sustaining losses from continuing operations. Because of the required allocation, we recorded an income tax benefit of $8.7 and $0.8 million for the nine months ended September 30, 2019 and 2018 , respectively, within “benefit for income taxes from continuing operations” and income tax expense of $7.2 million and $0.8 million , respectively, within “income from discontinued operations, net of income taxes” on the accompanying Condensed Consolidated Statements of Operations. For the three months ended September 30, 2019 and 2018 , we recorded an income tax benefit of $0.2 million and $0.1 million , respectively, within “benefit for income taxes from continuing operations,” and income tax expense of $0.2 million and $0.1 million , respectively, within “income from discontinued operations, net of income taxes” on the accompanying Condensed Consolidated Statements of Operations. Our net tax benefit for the three and nine months ended September 30, 2019 , prior to the application of intraperiod tax allocation guidance was $11 thousand and $1.5 million , respectively. The $1.5 million tax benefit arose from the reversal of deferred tax liabilities recorded on our Consolidated Balance Sheets as of December 31, 2018 that were associated with indefinite-lived intangible assets that were sold as part of our Commercial Product Portfolio Transaction. The tax expense for the three and nine months ended September 30, 2018 , prior to the application of intraperiod tax allocation guidance was $3 thousand and $8 thousand , respectively.

Discontinued Operations

Discontinued Operations	9 Months Ended
	Sep. 30, 2019
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	DISCONTINUED OPERATIONS Overview On March 1, 2019, we completed the Commercial Product Portfolio Transaction -- see Note 1(b) (as we first announced on January 17, 2019 on Form 8-K, upon the signing of a definitive asset purchase agreement). In accordance with applicable GAAP ( ASC 205-20, Presentation of Financial Statements ), the revenue-deriving activities and allocable expenses of our sold commercial operation, as well as the assets and liabilities connected to the Commercial Product Portfolio, are separately classified as “discontinued” for all periods presented within the accompanying Condensed Consolidated Statement of Operations and Condensed Consolidated Balance Sheet. Condensed Consolidated Statement of Operations The following table presents the various elements of “income from discontinued operations, net of income taxes” as reported in the accompanying Condensed Consolidated Statement of Operations: Three Months Ended Nine Months Ended 2019 2018 2019 2018 Product sales, net* $ 5,968 $ 24,556 $ 18,906 $ 76,419 License fees and service revenue — 712 290 3,511 Total revenues $ 5,968 $ 25,268 $ 19,196 $ 79,930 Operating costs and expenses: Cost of sales (excluding amortization of intangible assets) 5,115 6,472 8,716 19,892 Selling, general and administrative 69 6,730 5,959 21,279 Research and development (194 ) 5,745 2,597 15,167 Amortization of intangible assets — 6,923 1,248 20,803 Restructuring charges - employee severance ( Note 12 ) — — 3,858 — Total operating costs and expenses $ 4,990 $ 25,870 $ 22,378 $ 77,141 Income (loss) from discontinued operations $ 978 $ (602 ) $ (3,182 ) $ 2,789 Other (expense) income: Change in fair value of contingent consideration — 1,200 (1,478 ) 717 Gain on sale of Commercial Product Portfolio** (193 ) — 33,451 — Total other (expense) income $ (193 ) $ 1,200 $ 31,973 $ 717 Income from discontinued operations before income taxes 785 598 28,791 3,506 Provision for income taxes from discontinued operations*** (213 ) (144 ) (7,166 ) (847 ) Income from discontinued operations, net of income taxes $ 572 $ 454 $ 21,625 $ 2,659 * This revenue for the three and nine months ended September 30, 2019 includes: (i) sales from our Commercial Product Portfolio in January and February 2019 (prior to the completion of the Commercial Product Portfolio Transaction) and (ii) EVOMELA sales to a licensee during the second and third quarters of 2019 since a related supply contract was not assumed by Acrotech at the time of sale (see Note 7 ). ** This pre-tax gain on sale represents the $158.8 million gross proceeds from the Commercial Product Portfolio Transaction less our $121.2 book value of transferred net assets (inclusive of assumed liabilities) to Acrotech on the March 1, 2019 closing date less legal and banker fees aggregating $3.9 million . In the third quarter of 2019, we reduced this gain for a $0.2 million contract cancellation fee associated with our sold commercial operations; this value was deducted from the $4.0 million escrow account (reported as “restricted cash” on the accompanying Condensed Consolidated Balance Sheets until its release on November 5, 2019). *** This income tax provision represents an allocation of taxes as required under intraperiod allocation guidance (see Note 10 ). Due to our aggregate net operating loss-carryforwards, no federal or state income tax payments are expected to be made relating to our current year activity, inclusive of our recognized gain on sale of the Commercial Product Portfolio. Condensed Consolidated Balance Sheets Accounts receivable derived from our product sales on and prior to February 28, 2019 were not transferred to Acrotech as part of Commercial Product Portfolio Transaction, nor were our GTN liabilities and trade accounts payable assumed by Acrotech that were associated with our commercial activities on and prior to February 28, 2019 (see Note 3(g) ). Accordingly, these specific assets and liabilities remain presented within “accounts receivable, net of allowance for doubtful accounts” and “accounts payable and other accrued liabilities” on the accompanying Condensed Consolidated Balance Sheets. The following table presents a summary of our “discontinued operations, assets” and “discontinued operations, liabilities” as of December 31, 2018 within the accompanying Condensed Consolidated Balance Sheets (representing those assets and liabilities transferred to Acrotech as part of the Commercial Product Portfolio Transaction): December 31, 2018 Inventories $ 3,550 Prepaid expenses and other assets 2,005 Discontinued operations, current assets $ 5,555 Intangible assets, net of accumulated amortization 111,594 Goodwill 18,061 Other assets 2,970 Discontinued operations, non-current assets $ 132,625 FOLOTYN development liability 2,311 Discontinued operations, current liabilities $ 2,311 FOLOTYN development liability, less current portion 9,686 Acquisition-related contingent obligations 4,345 Discontinued operations, non-current liabilities $ 14,031 Condensed Consolidated Statement of Cash Flows The following table presents significant non-cash items for our discontinued operations that are included as adjustments in the accompanying Condensed Consolidated Statements of Cash Flows: Nine Months Ended 2019 2018 Depreciation and amortization $ 1,263 $ 20,871 Stock-based compensation $ 3,404 $ 4,626 Change in fair value of contingent consideration $ 1,478 $ (655 )

Restructuring Costs Related To

Restructuring Costs Related To Sale Of Commercial Product Portfolio	9 Months Ended
	Sep. 30, 2019
Restructuring and Related Activities [Abstract]
Restructuring Costs Related To Sale Of Commercial Product Portfolio	RESTRUCTURING COSTS RELATED TO SALE OF COMMERCIAL PRODUCT PORTFOLIO Employee Severance On March 1, 2019, we completed the Commercial Product Portfolio Transaction (see Note 1(b) ) and 87 of our employees were (1) terminated March 1, 2019 or (2) given notice of May 31, 2019 termination and asked to provide transition services for the benefit of Acrotech through that date (as provided by a transition services agreement with Acrotech entered contemporaneously with our sale). For the three and nine months ended September 30, 2019 , we recognized $0 and $0.7 million of income for services rendered to Acrotech under this agreement within “other income (expense), net” on our accompanying Condensed Consolidated Statements of Operations. The employees in (1) above were entitled to cash severance payments and acceleration of their unvested restricted stock awards and stock options. For the nine months ended September 30, 2019 , we fully recognized the aggregate value of $5.1 million for this severance benefit, of which $3.9 million , $1.0 million , and $0.2 million is included on the accompanying Condensed Consolidated Statements of Operations within “income from discontinued operations, net of income taxes” (see Note 11 ), “selling, general, and administrative” expenses and “research and development” expenses, respectively. The employees in (2) above were also entitled to cash severance payments and acceleration of their unvested restricted stock awards and stock options, though on May 31, 2019. The aggregate value of these one-time cash payments and stock-based award accelerations was $0.5 million . Due to then ongoing service requirements of these employees, we amortized this value through expense on a ratable basis beginning March 1, 2019 through May 31, 2019. For the three and nine months ended September 30, 2019 , we recognized $0 and $0.5 million for this severance benefit, which is included within “selling, general, and administrative” expenses on the accompanying Condensed Consolidated Statements of Operations, and within “accrued payroll and benefits” and “additional paid-in capital” (for stock-based awards) on the accompanying Condensed Consolidated Balance Sheets as of September 30, 2019 . Unpaid cash severance for our former employees was $0.4 million at September 30, 2019 and is recorded within “accrued payroll and benefits” on the accompanying Condensed Consolidated Balance Sheets.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Stockholders' Equity	STOCKHOLDERS’ EQUITY Sale of Common Stock Under ATM Agreement We entered into a new collective at-market-issuance (ATM) sales agreement with Cantor Fitzgerald & Co., H.C. Wainwright & Co., LLC and B. Riley FBR, Inc. (the “April 2019 ATM Agreement”) connected to our automatic shelf registration statement on Form S-3ASR, filed with the SEC on April 5, 2019. The April 2019 ATM Agreement allows us to raise aggregate gross proceeds of $150 million from the periodic sales of our common stock on the public market. Through September 30, 2019 , we raised aggregate net proceeds of $1.8 million under this ATM. These proceeds and any future proceeds raised will support the advancement of our in-development drug candidates, activities in connection with the launch of our in-development drug candidates, including hiring and building inventory supply, making acquisitions of assets, businesses, companies or securities, capital expenditures, and for working capital. Description of Financing Transaction No. of Common Shares Issued Proceeds Received Common shares issued pursuant to the April 2019 ATM Agreement during the nine months ended September 30, 2019 221,529 $ 1,814 There were no sales of our common shares under the April 2019 ATM Agreement during the three months ended September 30, 2019 .

Description of Business, Basi_2

Description of Business, Basis of Presentation, and Operating Segment (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Description of Business	Description of Business Spectrum Pharmaceuticals, Inc. (“Spectrum”, the “Company”, “we”, “our”, or “us”) is a biopharma company, with a primary strategy comprised of acquiring, developing, and commercializing novel and targeted oncology therapies. Our in-house development organization includes clinical development, regulatory, quality and data management, as well as commercial and marketing capabilities upon product launch. We have two drugs in late-stage development: • Poziotinib, a novel irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer (“NSCLC”) tumors with various mutations; and • ROLONTIS, a novel long-acting granulocyte colony-stimulating (“G-CSF”) for chemotherapy-induced neutropenia.
Basis of Presentation	Basis of Presentation Interim Financial Statements The interim financial data for the three and nine months ended September 30, 2019 and 2018 is unaudited and is not necessarily indicative of our operating results for a full year. In the opinion of our management, the interim data includes normal and recurring adjustments necessary for a fair presentation of our financial results for the three and nine months ended September 30, 2019 and 2018 . Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant to the Securities and Exchange Commission (“SEC”) rules and regulations relating to interim financial statements. The accompanying Condensed Consolidated Financial Statements should be read in conjunction with our audited Consolidated Financial Statements and Notes thereto included within our Annual Report on Form 10-K for the fiscal year ended December 31, 2018 (filed with the SEC on February 28, 2019 ). Discontinued Operations - Sale of our Commercial Product Portfolio On March 1, 2019, we completed the sale of our seven then-commercialized drugs, including FUSILEV, KHAPZORY, FOLOTYN, ZEVALIN , MARQIBO, BELEODAQ, and EVOMELA (the “Commercial Product Portfolio”) to Acrotech Biopharma LLC (“Acrotech”) (the “Commercial Product Portfolio Transaction”). Upon closing we received $158.8 million in an upfront cash payment (of which $4 million was held in escrow until November 5, 2019). We are also entitled to receive up to an aggregate of $140 million upon Acrotech's achievement of certain regulatory (totaling $40 million ) and sales-based milestones (totaling $100 million ) relating to the Commercial Product Portfolio. These Condensed Consolidated Financial Statements are recast for all periods presented to reflect the sale of the assets and liabilities associated with our Commercial Product Portfolio, as well as the corresponding revenue-deriving activities and allocable expenses of this commercial business within “discontinued operations” - see Note 11 . We have presented our face financial statements in general conformity with our historical format, even where presented values are $-0- within continuing operations due to required discontinued operations classification for all periods presented. We believe this format provides increased clarity and comparability with our previously filed financial statements, as well as our expectation that these financial statement captions and associated footnote disclosures will remain relevant to our future business activities. Principles of Consolidation The accompanying Condensed Consolidated Financial Statements have been prepared in accordance with GAAP and with the rules and regulations of the SEC. These financial statements include the financial position, results of operations, and cash flows of Spectrum and its subsidiaries, all of which are wholly-owned. All inter-company accounts and transactions among these legal entities have been eliminated in consolidation. In May 2019, we dissolved Spectrum Pharma Canada Inc., previously consolidated as a “variable interest entity” (as defined under applicable GAAP).
Operating Segment	Operating Segment We operate one reportable operating segment that is focused exclusively on developing (and eventually marketing) oncology and hematology drug products. For the three and nine months ended September 30, 2019 and 2018 , all of our revenue and operating costs and expenses were solely attributable to these activities (and as applicable, currently and retrospectively classified as “discontinued” within the accompanying Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Operations - see Note 11 ). All of our assets are held in the U.S, except for cash held in certain foreign bank accounts.
Revenue Recognition	Revenue Recognition On March 1, 2019, we completed the Commercial Product Portfolio Transaction -- see Note 1(b) . In accordance with applicable GAAP ( ASC 205-20, Presentation of Financial Statements ), the revenue-deriving activities of our sold commercial operation are separately classified as “discontinued” for all periods presented within the accompanying Condensed Consolidated Statements of Operations -- see Note 11 . Impact of the Adoption of the New Revenue Recognition Standard : ASU No. 2014-09 , Revenue from Contracts with Customers ( “Topic 606” ), became effective for us on January 1, 2018. Our disclosure within the below sections to this footnote reflects our updated accounting policies that are affected by this new standard. We applied the “modified retrospective” transition method for open contracts for the implementation of Topic 606; this resulted in the recognition of an aggregate $4.7 million , net of tax, decrease to our January 1, 2018 “accumulated deficit” on our accompanying Condensed Consolidated Balance Sheets for the cumulative impact of applying this new standard. We made no adjustments to our previously-reported total revenues, as those periods continue to be presented in accordance with our historical accounting practices under Topic 605, Revenue Recognition (“Topic 605”) . Required Elements of Our Revenue Recognition : Revenue from our (a) product sales, (b) out-license arrangements, and (c) service arrangements is recognized under Topic 606 in a manner that reasonably reflects the delivery of our goods and/or services to customers in return for expected consideration and includes the following elements: (1) we ensure that we have an executed contract(s) with our customer that we believe is legally enforceable; (2) we identify the “performance obligations” in the respective contract; (3) we determine the “transaction price” for each performance obligation in the respective contract; (4) we allocate the transaction price to each performance obligation; and (5) we recognize revenue only when we satisfy each performance obligation. These five elements, as applied to each of our revenue categories, are summarized below: (a) Product Sales : We sell our products to pharmaceutical wholesalers/distributors or to our product licensees (i.e., our customers). Our wholesalers/distributors in turn sell our products directly to clinics, hospitals, and private oncology-based practices. Revenue from our product sales is recognized as physical delivery of product occurs (when our customer obtains control of the product), in return for agreed-upon consideration. Our gross product sales (i.e., delivered units multiplied by the contractual price per unit) are reduced by our corresponding gross-to-net (“GTN”) estimates using the “expected value” method, resulting in reported “product sales, net” that reflects the amount we ultimately expect to realize in net cash proceeds, taking into account our current period gross sales and related cash receipts, and the subsequent cash disbursements on these sales that we estimate for the various GTN categories discussed below. These estimates are based upon information received from external sources (such as written or oral information obtained from our customers with respect to their period-end inventory levels and sales to end-users during the period), in combination with management’s informed judgments. Due to the inherent uncertainty of these estimates, the actual amount incurred (of some, or all) of product returns, government chargebacks, prompt pay discounts, commercial rebates, Medicaid rebates, and distribution, data, and GPO administrative fees may be materially above or below the amount estimated, then requiring prospective adjustments to our reported net product sales. These GTN estimate categories (that comprise our GTN liabilities within Note 3(g) ) are each discussed below: Product Returns Allowances : Our customers are contractually permitted to return certain purchased products within the contractual allowable time before/after its applicable expiration date. Returns outside of this aforementioned criteria are not customarily allowed. We estimate expected product returns using our historical return rates. Returned product is typically destroyed since substantially all are due to its imminent expiry and cannot be resold. Government Chargebacks : Our products are subject to pricing limits under certain federal government programs (e.g., Medicare and 340B Drug Pricing Program). Qualifying entities (i.e., end-users) purchase products from our customers at their qualifying discounted price. The chargeback amount we incur represents the difference between our contractual sales price to our customer, and the end-user’s applicable discounted purchase price under the government program. There may be significant lag time between our reported net product sales and our receipt of the corresponding government chargeback claims from our customers. Prompt Pay Discounts : Discounts for prompt payment are estimated at the time of sale, based on our eligible customers’ prompt payment history and the contractual discount percentage. Commercial Rebates : Commercial rebates are based on (i) our estimates of end-user purchases through a group purchasing organization (“GPO”), (ii) the corresponding contractual rebate percentage tier we expect each GPO to achieve, and (iii) our estimates of the impact of any prospective rebate program changes made by us. Medicaid Rebates : Our products are subject to state government-managed Medicaid programs, whereby rebates are issued to participating state governments. These rebates arise when a patient treated with our product is covered under Medicaid, resulting in a discounted price for our product under the applicable Medicaid program. Our Medicaid rebate accrual calculations require us to project the magnitude of our sales, by state, that will be subject to these rebates. There is a significant time lag in our receiving rebate notices from each state (generally several months or longer after our sale is recognized). Our estimates are based on our historical claim levels by state, as supplemented by management’s judgment. Distribution, Data, and GPO Administrative Fees : Distribution, data, and GPO administrative fees are paid to authorized wholesalers/distributors of our products for various commercial services including: contract administration, inventory management, delivery of end-user sales data, and product returns processing. These fees are based on a contractually-determined percentage of our applicable sales. (b) License Fees : Our out-license arrangements allow licensees to market our product(s) in certain territories for a specific term (representing the out-license of “functional intellectual property”). These arrangements may include one or more of the following forms of consideration: (i) upfront license fees, (ii) sales royalties, (iii) sales milestone-achievement fees, and (iv) regulatory milestone-achievement fees. We recognize revenue for each based on the contractual terms that establish our right to collect payment once the performance obligation is achieved, as follows: (1) Upfront License Fees: We determine whether upfront license fees are earned at the time of contract execution (i.e., when rights transfer to the customer) or over the actual (or implied) contractual period of the out-license. As part of this determination, we evaluate whether we have any other requirements to provide substantive services that are inseparable from the performance obligation of the license transfer. Our customers’ “distinct” rights to licensed “functional intellectual property” at the time of contract execution results in concurrent revenue recognition of all upfront license fees (assuming that there are no other performance obligations at contract execution that are inseparable from this license transfer). (2) Royalties : Under the “sales-or-usage-based royalty exception” we recognize revenue in the same period that our licensees complete product sales in their territory for which we are contractually entitled to a percentage-based royalty receipt. (3) Sales Milestones : Under the “sales-or-usage-based royalty exception” we recognize revenue in full within the period that our licensees achieve annual or aggregate product sales levels in their territories for which we are contractually entitled to a specified lump-sum receipt. (4) Regulatory Milestones : Under the terms of the respective out-license, regulatory achievements may either be our responsibility, or that of our licensee. • When our licensee is responsible for the achievement of the regulatory milestone, we recognize revenue in full (for the contractual amount due from our licensee) in the period that the approval occurs (i.e., when the “performance obligation” is satisfied by our customer) under the “most likely amount” method. This revenue recognition remains “constrained” (i.e., not recognized) until regulatory approval occurs, given its inherent uncertainty and the requirement of a significant revenue reversal not being probable if achievement does not occur. At each reporting period, we re-evaluate the probability of milestone achievement and the associated revenue constraint; any resulting adjustments would be recorded on a cumulative catch-up basis, thus reflected in our financial statements in the period of adjustment. • When we are responsible for the achievement of a regulatory milestone, the “relative selling price method” is applied for purposes of allocating the transaction price to our performance obligations. In such case, we consider (i) the extent of our effort to achieve the milestone and/or the enhancement of the value of the delivered item(s) as a result of milestone achievement and (ii) if the milestone payment is reasonable relative to all of the deliverables and payment terms (including other potential milestone consideration) within the arrangement. We have historically assessed the contractual value of these milestones upon their achievement to be identical to the allocation of value of our performance obligations and thus representing the “transaction price” for each milestone at contract inception. We recognize this revenue in the period that the regulatory approval occurs (i.e., when we complete the “performance obligation”) under the “most likely amount” method, and revenue recognition is otherwise “constrained” until regulatory approval occurs, given its inherent uncertainty and the requirement of a significant revenue reversal not being probable if achievement does not occur. At each reporting period, we re-evaluate the probability of milestone achievement and the associated revenue constraint; any resulting adjustments would be recorded on a cumulative catch-up basis, thus reflected in our financial statements in the period of adjustment. (c) Service Revenue : We receive fees under certain arrangements for (i) sales and marketing services, (ii) supply chain services, (iii) research and development services, and (iv) clinical trial management services. Our rights to receive payment for these services may be established by (1) a fixed-fee schedule that covers the term of the arrangement, so long as we meet ongoing performance obligations, (2) our completion of product delivery in our capacity as a procurement agent, (3) the successful completion of a phase of drug development, (4) favorable results from a clinical trial, and/or (5) regulatory approval events. We consider whether revenue associated with these service arrangements is reportable each period, based on our completed services or deliverables (i.e., satisfied “performance obligations”) during the reporting period, and the terms of the arrangement that contractually result in fixed payments due to us. The promised service(s) within these arrangements are distinct and explicitly stated within each contract, and our customer benefits from the separable service(s) delivery/completion. Further, the nature of the promise to our customer as stated within the respective contract is to deliver each named service individually (not a transfer of combined items to which the promised goods or services are inputs), and thus are separable for revenue recognition.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist of bank deposits and highly liquid investments with maturities of three months or less from the purchase date. Our restricted cash is currently held in an escrow account as part of our completed Commercial Product Portfolio Transaction (see Note 1(b) ).
Marketable Securities	Marketable Securities Marketable securities consist of our holdings in equity securities, mutual funds, bank certificates of deposit (“Bank CDs”), government-related debt securities, and corporate debt securities. Since we classify these investments as “available-for-sale” any (1) realized gains (losses) or (2) unrealized gains (losses) on these securities are respectively recognized in (1) “other income (expense), net” on the accompanying Condensed Consolidated Statements of Operations, or recognized in (2) “accumulated other comprehensive loss” as a separate component of stockholder’s equity on the accompanying Condensed Consolidated Statements of Stockholders’ Equity.
Accounts Receivable	Accounts Receivable Our accounts receivable are derived from our product sales and license fees, and do not bear interest. The allowance for doubtful accounts is management’s best estimate of the amount of probable credit losses in our existing accounts receivable. Account balances are charged off against the allowance after appropriate collection efforts are exhausted.
Inventories	Inventories We value our inventory at the lower of (i) the actual cost of its purchase or manufacture, or (ii) its net realizable value. Inventory cost is determined on the first-in, first-out method. We regularly review our inventory quantities in process of manufacture and on hand. When appropriate, we record a provision for obsolete and excess inventory to derive its new cost basis, which takes into account our sales forecast by product and corresponding expiry dates of each product lot. Manufacturing costs of drug products that are pending U.S. Food and Drug Administration (“FDA”) approval are exclusively recognized through “research and development” expense on the accompanying Condensed Consolidated Statements of Operations.
Stock-Based Compensation	Stock-Based Compensation Stock-based compensation expense for equity awards granted to our employees and members of our Board of Directors is recognized on a straight-line basis over each award’s vesting period. Recognized compensation expense is net of an estimated forfeiture rate, representing the percentage of awards that are expected to be forfeited prior to vesting, though is ultimately adjusted for actual forfeitures. We use the Black-Scholes option pricing model to determine the fair value of stock options (as of the date of grant) that have service conditions for vesting. We use the Monte Carlo valuation model to value equity awards (as of the date of grant) that have combined market conditions and service conditions for vesting. The recognition of stock-based compensation expense and the initial calculation of stock option fair value requires uncertain assumptions, including (a) the pre-vesting forfeiture rate of the award, (b) the expected term that the stock option will remain outstanding, (c) our stock price volatility over the expected term (and that of our designated peer group with respect to certain market-based awards), and (d) the prevailing risk-free interest rate for the period matching the expected term. With regard to (a)-(d) above: we estimate forfeiture rates based on our employees’ overall forfeiture history, which we believe will be representative of future results. We estimate the expected term of stock options granted based on our employees’ historical exercise patterns, which we believe will be representative of their future behavior. We estimate the volatility of our common stock on the date of grant based on the historical volatility of our common stock for a look-back period that corresponds with the expected term. We estimate the risk-free interest rate based upon the U.S. Department of the Treasury yields in effect at award grant, for a period equaling the expected term of the stock option.
Basic and Diluted Net Loss per Share	Basic and Diluted Net Loss per Share We calculate basic and diluted net loss per share using the weighted average number of common shares outstanding during the periods presented. In periods of a net loss, basic and diluted loss per share are the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include only dilutive stock options, warrants, and other common stock equivalents outstanding during the period.
Income Taxes	Income Taxes Deferred tax assets and liabilities are recorded based on the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the financial statements, as well as operating losses and tax credit carry forwards using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain. We have recorded a valuation allowance to reduce our deferred tax assets, because we believe that, based upon a weighting of positive and negative factors, it is more likely than not that these deferred tax assets will not be realized. If/when we were to determine that our deferred tax assets are realizable, an adjustment to the corresponding valuation allowance would increase our net income in the period that such determination was made. In the event that we are assessed interest and/or penalties from taxing authorities that have not been previously accrued, such amounts would be included in “benefit for income taxes from continuing operations” within the accompanying Condensed Consolidated Statements of Operations for the period in which we received the notice.
Research and Development Costs	Research and Development Costs Our research and development costs are expensed as incurred (see Note 9(c) ) or as certain milestone payments become contractually due to our licensors, as triggered by the achievement of clinical or regulatory events.
Fair Value Measurements	Fair Value Measurements We determine measurement-date fair value based on the proceeds that would be received through the sale of the asset, or that we would pay to settle or transfer the liability, in an orderly transaction between market participants. We utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include the following: Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date. Level 2: Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public. Level 3: Unobservable inputs are used when little or no market data is available.

Balance Sheet Account Detail (T

Balance Sheet Account Detail (Tables)	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash, Cash Equivalents and Investments	The following is a summary of our presented composition of “cash and cash equivalents” and “marketable securities”: Historical or Amortized Cost Foreign Currency Translation Unrealized Cash and Cash Marketable Securities September 30, 2019 Equity securities* (see Note 7 ) $ 8,710 $ (5,285 ) $ 30,134 $ — $ 33,559 $ — $ 33,559 Money market funds 89,041 — — — 89,041 89,041 — Government-related debt securities** 60,087 — 55 — 60,142 — 60,142 Corporate debt securities** 44,182 — 47 (5 ) 44,224 20,913 23,311 Bank deposits 14,644 — — — 14,644 14,644 — Bank CDs 6,126 — 26 — 6,152 — 6,152 Total cash and cash equivalents and marketable securities $ 222,790 $ (5,285 ) $ 30,262 $ (5 ) $ 247,762 $ 124,598 $ 123,164 December 31, 2018 Equity securities* (see Note 7 ) $ 8,710 $ (2,168 ) $ 39,880 $ — $ 46,422 $ — $ 46,422 Money market funds 142,745 — — — 142,745 142,745 — Bank deposits 14,735 — — — 14,735 14,735 — Bank CDs 86 — — — 86 — 86 Total cash and cash equivalents and marketable securities $ 166,276 $ (2,168 ) $ 39,880 $ — $ 203,988 $ 157,480 $ 46,508 * Beginning January 1, 2018, under the requirements of ASU 2016-01, Recognition and Measurement of Financial Assets and Liabilities , the unrealized gain (loss) on our CASI equity securities are recognized as an increase (decrease) to “other income (expense), net” on the Condensed Consolidated Statements of Operations (rather than through “other comprehensive loss”) on the Condensed Consolidated Statements of Comprehensive Loss). Our adoption of ASU 2016-01 on January 1, 2018 resulted in a $17.2 million cumulative-effect adjustment, net of income tax, reported as a decrease to “accumulated other comprehensive loss” and a decrease to “accumulated deficit” on the accompanying Condensed Consolidated Balance Sheets. Our unrealized gains (losses) on these equity securities for the three and nine months ended September 30, 2019 was $2.0 million and ($9.7) million , respectively, as reported in “other income (expense), net” on the accompanying Condensed Consolidated Statements of Operations. ** Beginning in the second quarter of 2019, we purchased certain government and corporate debt securities. We have classified these as “available-for-sale” since we may redeem or sell these investments before their stated maturity to fund our operations. Under the requirements of ASC 320, Investments - Debt and Equity Securities: (i) we recorded these securities at initial “book value” and then amortize, through maturity, the determined “discount” or “premium” within “interest income” on the accompanying Condensed Consolidated Statements of Operations, and (ii) we recognize the “unrealized gains (loss)” of these securities (i.e., fair value versus amortized book value) as a separate component of “other comprehensive loss” on the accompanying Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2019
Schedule of Property and Equipment Net of Accumulated Depreciation	“Property and equipment, net of accumulated depreciation” consists of the following: September 30, 2019 December 31, 2018 Manufacturing equipment* $ 7,601 $ — Computer hardware and software 3,589 3,079 Laboratory equipment 669 635 Leasehold improvements 3,389 2,957 Office furniture 335 212 Property and equipment, at cost 15,583 6,883 (Less): Accumulated depreciation (6,618 ) (6,498 ) Property and equipment, net of accumulated depreciation $ 8,965 $ 385 * This represents owned ROLONTIS production equipment on location at our contract manufacturer.
Prepaid Expenses and Other Assets	“Prepaid expenses and other assets” consists of the following: September 30, 2019 December 31, 2018 Vendor deposits $ 12,628 $ 6,792 Prepaid insurance 52 782 Prepaid expenses and other assets $ 12,680 $ 7,574
Schedule of Other Receivables	“Other receivables” consists of the following: September 30, 2019 December 31, 2018 Insurance receivable* $ 4,781 $ 206 Other miscellaneous receivables (including Medicaid rebate credits and royalty receivables from licensees) 1,549 1,189 Secured promissory note (see Note 7 ) — 1,525 Income tax receivable - current portion 632 643 Interest receivable from marketable securities (see Note 3(a) ) 627 — Reimbursements due from development partners for incurred research and development expenses 163 135 Other receivables $ 7,752 $ 3,698 * This insurance receivable balance represents our incurred legal fees and pending and completed settlements that are expected to be reimbursed by our insurance carriers.
Summary of Other Assets	“Other assets” consists of the following: September 30, 2019 December 31, 2018 Key employee life insurance – cash surrender value associated with deferred compensation plan ( Note 9(f) ) $ 7,882 $ 6,274 Income tax receivable - non-current portion* 668 668 Research & development supplies and other 63 246 Other assets $ 8,613 $ 7,188 * This value represents the non-current portion of refundable alternative minimum tax payments made that are expected to be received over the next few years (see Note 10 ).
Facility and Equipment Under Lease	“Facility and equipment under lease” consists of the following : September 30, 2019 December 31, 2018 Office and research facilities $ 3,092 $ — Office equipment 439 — Facility and equipment under lease ( Note 9(a) ) $ 3,531 $ — The below table summarizes these lease asset and liability accounts presented on our accompanying Condensed Consolidated Balance Sheets: Operating Leases* Condensed Consolidated Balance Sheet Caption Balance as of September 30, 2019 Operating lease right-of-use assets - non-current Facility and equipment under lease $ 3,531 Operating lease liabilities - current Accounts payable and other accrued liabilities $ 326 Operating lease liabilities - non-current Other long-term liabilities 3,429 Total operating lease liabilities $ 3,755 * As of September 30, 2019 , we have no “finance leases” as defined in Topic 842 .
Schedule of Accounts Payable and Other Accrued Liabilities	“Accounts payable and other accrued liabilities” consists of the following : September 30, 2019 December 31, 2018 Trade accounts payable and other $ 30,321 $ 44,919 Lease liability - current portion ( Note 9(a) ) 326 — Accrued commercial/Medicaid rebates 3,058 8,371 Accrued product royalty due to licensors 58 4,337 Allowance for product returns 4,985 5,171 Accrued data and distribution fees 832 3,248 Accrued GPO administrative fees 11 296 Accrued inventory management fees 368 388 Allowance for government chargebacks — 2,730 Accounts payable and other accrued liabilities $ 39,959 $ 69,460
Schedule of Amounts Presented in Accounts Payable and Other Accrued Liabilities	Amounts presented within “accounts payable and other accrued liabilities” in the accompanying Condensed Consolidated Balance Sheets for our categories of GTN estimates (see Note 2(i) ) were as follows: Commercial/Medicaid Rebates and Government Chargebacks Distribution, Data, Inventory and Product Return Allowances Balance as of December 31, 2017 $ 10,358 $ 5,727 $ 4,045 Add: GTN accruals recorded for product sales 65,751 13,962 1,700 (Less): Payments made and credits against GTN accruals (65,008 ) (15,757 ) (574 ) Balance as of December 31, 2018 $ 11,101 $ 3,932 $ 5,171 Add: GTN accruals recorded for product sales 7,252 1,197 167 (Less): Payments made and credits against GTN accruals (15,295 ) (3,918 ) (353 ) Balance as of September 30, 2019 $ 3,058 $ 1,211 $ 4,985
Schedule of Contract liabilities	“Contract liabilities” consists of the following: September 30, 2019 December 31, 2018 Customer deposit for EVOMELA supply in China territory ( see Note 7 ) $ 1,360 $ 4,850 Contract liabilities $ 1,360 $ 4,850
Summary of Other Long-Term Liabilities	“Other long-term liabilities” consists of the following: September 30, 2019 December 31, 2018 Deferred compensation liability ( Note 9(f) ) $ 7,708 $ 5,474 Lease liability - non-current portion ( Note 9(a) ) 3,429 — Other tax liabilities 176 176 Other long-term liabilities $ 11,313 $ 5,650

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
Summary of Stock-Based Compensation Expense	Stock-based compensation expense, included within “total operating costs and expenses” for the three and nine months ended September 30, 2019 and 2018 , was as follows: Three Months Ended Nine Months Ended 2019 2018 2019 2018 Selling, general and administrative $ 3,156 $ 1,902 $ 10,550 $ 6,686 Research and development 1,030 603 3,251 1,884 Total stock-based compensation $ 4,186 $ 2,505 $ 13,801 $ 8,570

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Computation of Net Loss Per Share	Net loss per share was computed by dividing net loss by the weighted average number of common shares outstanding for the three and nine months ended September 30, 2019 and 2018 : Three Months Ended Nine Months Ended 2019 2018 2019 2018 Weighted average shares outstanding - basic and diluted 111,178,880 104,106,295 110,291,090 102,571,850 Net loss $ (25,985 ) $ (68,718 ) $ (73,535 ) $ (70,792 ) Net loss per share – basic and diluted $ (0.23 ) $ (0.66 ) $ (0.67 ) $ (0.69 )
Schedule of Securities Excluded from Calculation of Net Loss Per Share	The below outstanding securities for the three and nine months ended September 30, 2019 and 2018 , were excluded from the above calculation of net loss because their impact under the “treasury stock method” and “if-converted method” would have been anti-dilutive due to our net loss per share in each respective period, as summarized below. Three Months Ended Nine Months Ended 2019 2018 2019 2018 Common stock options issued 635,175 3,702,092 1,198,358 4,175,866 Restricted stock awards issued 1,695,123 1,751,876 1,695,123 1,751,876 Restricted stock units issued 385,919 245,214 385,919 245,214 Employee stock purchase plan shares pending issuance 30,823 21,033 30,823 21,033 2013 Convertible Notes outstanding- if converted into common shares — 3,403,659 — 3,403,659 Total 2,747,040 9,123,874 3,310,223 9,597,648

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Summary of Asset and Liability Fair Values	The table below summarizes certain asset and liability fair values that are included within our accompanying Condensed Consolidated Balance Sheets, and their designations among the three fair value measurement categories (see Note 2(x)) : September 30, 2019 Level 1 Level 2 Level 3 Total Assets: Equity securities ( Note 7 ) $ 33,559 $ — $ — $ 33,559 Bank CDs — 6,152 — 6,152 Mutual funds — 29 — 29 Restricted cash 4,040 — — 4,040 Deferred compensation investments (life insurance cash surrender value ( Note 3(e) ) — 7,882 — 7,882 * Money market funds 89,041 — — 89,041 Government-related debt securities 37,448 22,694 — 60,142 Corporate debt securities — 44,224 — 44,224 $ 164,088 $ 80,981 $ — $ 245,069 Liabilities: Deferred compensation liability ( Note 9(f) ) $ — $ 7,848 $ — $ 7,848 * $ — $ 7,848 $ — $ 7,848 December 31, 2018 Level 1 Level 2 Level 3 Total Assets: Bank CDs $ — $ 86 $ — $ 86 Money market funds — 142,745 — 142,745 Equity securities ( Note 7 ) 46,422 — — 46,422 Mutual funds — 78 — 78 Deferred compensation investments (life insurance cash surrender value ( Note 3(e) ) — 6,274 — 6,274 * $ 46,422 $ 149,183 $ — $ 195,605 Liabilities: Deferred compensation liability ( Note 9(f) ) $ — $ 6,167 $ — $ 6,167 * $ — $ 6,167 $ — $ 6,167 * The reported amount of “deferred compensation investments” is based on the cash surrender value of life insurance policies of named current and former employees at each period-end. The reported amount of “deferred executive compensation liability” is based on the period-end market value of mutual fund investments selected by employee participants of the deferred compensation plan.

Convertible Senior Notes and _2

Convertible Senior Notes and Interest Expense (Tables)	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Components of the Interest Expense Recognized	The following table sets forth the components of interest expense recognized in the accompanying Condensed Consolidated Statements of Operations for the 2013 Convertible Notes. Three Months Ended September 30, 2018 Nine Months Ended September 30, 2018 Stated coupon interest expense $ 246 $ 798 Amortization of debt issuance costs 56 178 Accretion of debt discount 491 1,558 Total interest expense $ 793 $ 2,534 Effective interest rate 8.4 % 8.4 %

Financial Commitments & Conti_2

Financial Commitments & Contingencies and Key License Agreements (Tables)	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Assets And Liabilities, Leases	“Facility and equipment under lease” consists of the following : September 30, 2019 December 31, 2018 Office and research facilities $ 3,092 $ — Office equipment 439 — Facility and equipment under lease ( Note 9(a) ) $ 3,531 $ — The below table summarizes these lease asset and liability accounts presented on our accompanying Condensed Consolidated Balance Sheets: Operating Leases* Condensed Consolidated Balance Sheet Caption Balance as of September 30, 2019 Operating lease right-of-use assets - non-current Facility and equipment under lease $ 3,531 Operating lease liabilities - current Accounts payable and other accrued liabilities $ 326 Operating lease liabilities - non-current Other long-term liabilities 3,429 Total operating lease liabilities $ 3,755 * As of September 30, 2019 , we have no “finance leases” as defined in Topic 842 .
Lease, Cost	The components of our aggregate lease expense is summarized below: Three Months Ended September 30, 2019 Nine Months Ended September 30, 2019 Operating lease cost $ 351 $ 1,202 Variable lease cost 108 323 Short-term lease cost 20 59 Total lease cost $ 479 $ 1,584 Weighted Average Remaining Lease Term and Applied Discount Rate Weighted Average Remaining Lease Term Weighted Average Discount Rate Operating leases as of September 30, 2019 3 years 7.8%
Lessee, Operating Lease, Liability, Maturity	The below table summarizes our (i) minimum lease payments over the next five years, (ii) lease arrangement implied interest, and (iii) present value of future lease payments: Operating Leases - future payments September 30, 2019 2019 (remaining) $ 383 2020 1,441 2021 1,465 2022 828 2023 87 Total future lease payments, undiscounted $ 4,204 (Less): Implied interest (449 ) Present value of operating lease payments $ 3,755
Schedule of Future Minimum Rental Payments for Operating Leases	The below is required tabular disclosure for comparative purposes with our current period-end balance sheet date above: Operating Leases - future payments December 31, 2018 2019 $ 1,486 2020 1,441 2021 1,465 2022 828 2023 and thereafter 87 $ 5,308

Discontinued Operations (Tables

Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2019
Discontinued Operations and Disposal Groups [Abstract]
Disposal Groups, Including Discontinued Operations	The following table presents the various elements of “income from discontinued operations, net of income taxes” as reported in the accompanying Condensed Consolidated Statement of Operations: Three Months Ended Nine Months Ended 2019 2018 2019 2018 Product sales, net* $ 5,968 $ 24,556 $ 18,906 $ 76,419 License fees and service revenue — 712 290 3,511 Total revenues $ 5,968 $ 25,268 $ 19,196 $ 79,930 Operating costs and expenses: Cost of sales (excluding amortization of intangible assets) 5,115 6,472 8,716 19,892 Selling, general and administrative 69 6,730 5,959 21,279 Research and development (194 ) 5,745 2,597 15,167 Amortization of intangible assets — 6,923 1,248 20,803 Restructuring charges - employee severance ( Note 12 ) — — 3,858 — Total operating costs and expenses $ 4,990 $ 25,870 $ 22,378 $ 77,141 Income (loss) from discontinued operations $ 978 $ (602 ) $ (3,182 ) $ 2,789 Other (expense) income: Change in fair value of contingent consideration — 1,200 (1,478 ) 717 Gain on sale of Commercial Product Portfolio** (193 ) — 33,451 — Total other (expense) income $ (193 ) $ 1,200 $ 31,973 $ 717 Income from discontinued operations before income taxes 785 598 28,791 3,506 Provision for income taxes from discontinued operations*** (213 ) (144 ) (7,166 ) (847 ) Income from discontinued operations, net of income taxes $ 572 $ 454 $ 21,625 $ 2,659 * This revenue for the three and nine months ended September 30, 2019 includes: (i) sales from our Commercial Product Portfolio in January and February 2019 (prior to the completion of the Commercial Product Portfolio Transaction) and (ii) EVOMELA sales to a licensee during the second and third quarters of 2019 since a related supply contract was not assumed by Acrotech at the time of sale (see Note 7 ). ** This pre-tax gain on sale represents the $158.8 million gross proceeds from the Commercial Product Portfolio Transaction less our $121.2 book value of transferred net assets (inclusive of assumed liabilities) to Acrotech on the March 1, 2019 closing date less legal and banker fees aggregating $3.9 million . In the third quarter of 2019, we reduced this gain for a $0.2 million contract cancellation fee associated with our sold commercial operations; this value was deducted from the $4.0 million escrow account (reported as “restricted cash” on the accompanying Condensed Consolidated Balance Sheets until its release on November 5, 2019). *** This income tax provision represents an allocation of taxes as required under intraperiod allocation guidance (see Note 10 ). Due to our aggregate net operating loss-carryforwards, no federal or state income tax payments are expected to be made relating to our current year activity, inclusive of our recognized gain on sale of the Commercial Product Portfolio. Condensed Consolidated Balance Sheets Accounts receivable derived from our product sales on and prior to February 28, 2019 were not transferred to Acrotech as part of Commercial Product Portfolio Transaction, nor were our GTN liabilities and trade accounts payable assumed by Acrotech that were associated with our commercial activities on and prior to February 28, 2019 (see Note 3(g) ). Accordingly, these specific assets and liabilities remain presented within “accounts receivable, net of allowance for doubtful accounts” and “accounts payable and other accrued liabilities” on the accompanying Condensed Consolidated Balance Sheets. The following table presents a summary of our “discontinued operations, assets” and “discontinued operations, liabilities” as of December 31, 2018 within the accompanying Condensed Consolidated Balance Sheets (representing those assets and liabilities transferred to Acrotech as part of the Commercial Product Portfolio Transaction): December 31, 2018 Inventories $ 3,550 Prepaid expenses and other assets 2,005 Discontinued operations, current assets $ 5,555 Intangible assets, net of accumulated amortization 111,594 Goodwill 18,061 Other assets 2,970 Discontinued operations, non-current assets $ 132,625 FOLOTYN development liability 2,311 Discontinued operations, current liabilities $ 2,311 FOLOTYN development liability, less current portion 9,686 Acquisition-related contingent obligations 4,345 Discontinued operations, non-current liabilities $ 14,031 Condensed Consolidated Statement of Cash Flows The following table presents significant non-cash items for our discontinued operations that are included as adjustments in the accompanying Condensed Consolidated Statements of Cash Flows: Nine Months Ended 2019 2018 Depreciation and amortization $ 1,263 $ 20,871 Stock-based compensation $ 3,404 $ 4,626 Change in fair value of contingent consideration $ 1,478 $ (655 )

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Schedule of Stock by Class	Description of Financing Transaction No. of Common Shares Issued Proceeds Received Common shares issued pursuant to the April 2019 ATM Agreement during the nine months ended September 30, 2019 221,529 $ 1,814

Description of Business, Basi_3

Description of Business, Basis of Presentation, and Operating Segment (Details) $ in Millions	Mar. 01, 2019USD ($)product	Sep. 30, 2019USD ($)productSegment
Segment Reporting Information [Line Items]
Number of late stage development products | product		2
Number of reportable operating segment | Segment		1
Discontinued Operations, Disposed of by Sale [Member] | Commercial Product Portfolio [Member]
Segment Reporting Information [Line Items]
Number of products | product	7
Disposal group, including discontinued operation, consideration	$ 158.8
Escrow deposits	4	$ 4
Aggregate amount receivable based on achievement of milestones	140
Payments receivable based on achievement of regulatory milestones	40
Potential payments based on achievement of sales milestones	$ 100

Summary of Significant Accoun_2

Summary of Significant Accounting Policies and Use of Estimates (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018	Jan. 01, 2018
Accounting Policies [Line Items]
Increase (decrease) in retained earnings due to revenue recognition	$ (673,421)	$ (599,886)
Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]
Accounting Policies [Line Items]
Increase (decrease) in retained earnings due to revenue recognition			$ 4,700

Balance Sheet Account Detail -

Balance Sheet Account Detail - Summary of Cash and Cash Equivalents and Marketable Securities (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Jan. 01, 2018
Schedule of Investments [Line Items]
Cost of equity securities	$ 8,710		$ 8,710
Foreign currency translation on equity securities	(5,285)		(2,168)
Gross unrealized gain on equity securities	30,134		39,880
Equity securities (Note 7)	33,559		46,422
Cash, cash equivalents and short-term investments, amortized cost	222,790		166,276
Cash and cash equivalents and short-term investments, accumulated unrealized gain	30,262
Cash, cash equivalents, and short-term investments, accumulated unrealized loss	(5)		0
Cash, cash equivalents, and short-term investments	247,762		203,988
Equity securities, unrealized gain (loss)	2,000	$ (9,700)
Accounting Standards Update 2016-01 [Member]
Schedule of Investments [Line Items]
Cumulative effect of new accounting principle in period of adoption				$ 0
Retained Earnings [Member] | Accounting Standards Update 2016-01 [Member]
Schedule of Investments [Line Items]
Cumulative effect of new accounting principle in period of adoption				17,211
AOCI Attributable to Parent [Member] | Accounting Standards Update 2016-01 [Member]
Schedule of Investments [Line Items]
Cumulative effect of new accounting principle in period of adoption				$ (17,211)
Money market funds [Member]
Schedule of Investments [Line Items]
Available-for-sale, debt securities, amortized cost	89,041		142,745
Available-for-sale, debt securities, estimated fair value	89,041		142,745
US Government Debt Securities [Member]
Schedule of Investments [Line Items]
Available-for-sale, debt securities, amortized cost	60,087
Debt securities, available-for-sale, unrealized gain	55
Available-for-sale, debt securities, estimated fair value	60,142
Corporate Debt Securities [Member]
Schedule of Investments [Line Items]
Available-for-sale, debt securities, amortized cost	44,182
Debt securities, available-for-sale, unrealized gain	47
Debt securities, available-for-sale, unrealized loss	(5)
Available-for-sale, debt securities, estimated fair value	44,224
Bank Deposits [Member]
Schedule of Investments [Line Items]
Available-for-sale, debt securities, amortized cost	14,644		14,735
Debt securities, available-for-sale, unrealized gain	0
Available-for-sale, debt securities, estimated fair value	14,644		14,735
Bank CDs [Member]
Schedule of Investments [Line Items]
Available-for-sale, debt securities, amortized cost	6,126		86
Debt securities, available-for-sale, unrealized gain	26
Available-for-sale, debt securities, estimated fair value	6,152		86
Cash and Cash Equivalents [Member]
Schedule of Investments [Line Items]
Cash, cash equivalents, and short-term investments	124,598		157,480
Cash and Cash Equivalents [Member] | Money market funds [Member]
Schedule of Investments [Line Items]
Available-for-sale, debt securities, estimated fair value	89,041		142,745
Cash and Cash Equivalents [Member] | US Government Debt Securities [Member]
Schedule of Investments [Line Items]
Available-for-sale, debt securities, estimated fair value	0
Cash and Cash Equivalents [Member] | Corporate Debt Securities [Member]
Schedule of Investments [Line Items]
Available-for-sale, debt securities, estimated fair value	20,913
Cash and Cash Equivalents [Member] | Bank Deposits [Member]
Schedule of Investments [Line Items]
Available-for-sale, debt securities, estimated fair value	14,644		14,735
Short-term Investments [Member]
Schedule of Investments [Line Items]
Equity securities (Note 7)	33,559		46,422
Cash, cash equivalents, and short-term investments	123,164		46,508
Short-term Investments [Member] | US Government Debt Securities [Member]
Schedule of Investments [Line Items]
Available-for-sale, debt securities, estimated fair value	60,142
Short-term Investments [Member] | Corporate Debt Securities [Member]
Schedule of Investments [Line Items]
Available-for-sale, debt securities, estimated fair value	23,311
Short-term Investments [Member] | Bank Deposits [Member]
Schedule of Investments [Line Items]
Available-for-sale, debt securities, estimated fair value	0
Short-term Investments [Member] | Bank CDs [Member]
Schedule of Investments [Line Items]
Available-for-sale, debt securities, estimated fair value	$ 6,152		$ 86

Balance Sheet Account Detail _2

Balance Sheet Account Detail - Schedule of Property and Equipment Net of Accumulated Depreciation (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	$ 15,583	$ 6,883
(Less): Accumulated depreciation	(6,618)	(6,498)
Property and equipment, net of accumulated depreciation	8,965	385
Manufacturing Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	7,601	0
Computer hardware and software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	3,589	3,079
Laboratory equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	669	635
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	3,389	2,957
Office furniture [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	$ 335	$ 212

Balance Sheet Account Detail _3

Balance Sheet Account Detail - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Depreciation	$ 0.1	$ 0.1	$ 0.2	$ 0.2

Balance Sheet Account Detail _4

Balance Sheet Account Detail - Prepaid Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Vendor deposits	$ 12,628	$ 6,792
Prepaid insurance	52	782
Prepaid expenses and other assets	$ 12,680	$ 7,574

Balance Sheet Account Detail _5

Balance Sheet Account Detail - Schedule of Other Receivables (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Insurance receivable	$ 4,781	$ 206
Other miscellaneous receivables (including Medicaid rebate credits and royalty receivables from licensees)	1,549	1,189
Secured promissory note (see Note 7)	0	1,525
Income tax receivable - current portion	632	643
Interest receivable from marketable securities (see Note 3(a))	627	0
Reimbursements due from development partners for incurred research and development expenses	163	135
Other receivables	$ 7,752	$ 3,698

Balance Sheet Account Detail _6

Balance Sheet Account Detail - Summary of Other Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Key employee life insurance – cash surrender value associated with deferred compensation plan (Note 9(f))	$ 7,882	$ 6,274
Income tax receivable - non-current portion	668	668
Research & development supplies and other	63	246
Other assets	$ 8,613	$ 7,188

Balance Sheet Account Detail _7

Balance Sheet Account Detail - Facility and Equipment Under Lease (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Lessee, Lease, Description [Line Items]
Facility and equipment under lease (Note 9(a))	$ 3,531	$ 0
Building [Member]
Lessee, Lease, Description [Line Items]
Facility and equipment under lease (Note 9(a))	3,092	0
Office Equipment [Member]
Lessee, Lease, Description [Line Items]
Facility and equipment under lease (Note 9(a))	$ 439	$ 0

Balance Sheet Account Detail _8

Balance Sheet Account Detail - Schedule of Accounts Payable and Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Trade accounts payable and other	$ 30,321	$ 44,919
Lease liability - current portion (Note 9(a))	326	0
Accrued commercial/Medicaid rebates	3,058	8,371
Accrued product royalty due to licensors	58	4,337
Allowance for product returns	4,985	5,171
Accrued data and distribution fees	832	3,248
Accrued GPO administrative fees	11	296
Accrued inventory management fees	368	388
Allowance for government chargebacks	0	2,730
Accounts payable and other accrued liabilities	$ 39,959	$ 69,460

Balance Sheet Account Detail _9

Balance Sheet Account Detail - Schedule of Amounts Presented in Accounts Payable and Other Accrued Liabilities (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Commercial/Medicaid Rebates and Government Chargebacks [Member]
Accounts Payable and Other Liabilities [Roll Forward]
Beginning balance	$ 11,101	$ 10,358
Add: GTN accruals recorded for product sales	7,252	65,751
(Less): Payments made and credits against GTN accruals	(15,295)	(65,008)
Ending balance	3,058	11,101
Distribution, Data, Inventory and GPO Administrative Fees [Member]
Accounts Payable and Other Liabilities [Roll Forward]
Beginning balance	3,932	5,727
Add: GTN accruals recorded for product sales	1,197	13,962
(Less): Payments made and credits against GTN accruals	(3,918)	(15,757)
Ending balance	1,211	3,932
Product Return Allowances [Member]
Accounts Payable and Other Liabilities [Roll Forward]
Beginning balance	5,171	4,045
Add: GTN accruals recorded for product sales	167	1,700
(Less): Payments made and credits against GTN accruals	(353)	(574)
Ending balance	$ 4,985	$ 5,171

Balance Sheet Account Detail_10

Balance Sheet Account Detail - Deferred Revenue (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Contract liabilities	$ 1,360	$ 4,850

Balance Sheet Account Detail_11

Balance Sheet Account Detail - Summary of Other Long-Term Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Deferred compensation liability (Note 9(f))	$ 7,708	$ 5,474
Lease liability - non-current portion (Note 9(a))	3,429	0
Other tax liabilities	176	176
Other long-term liabilities	$ 11,313	$ 5,650

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation	$ 4,186	$ 2,505	$ 13,801	$ 8,570
Selling, general and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation	3,156	1,902	10,550	6,686
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation	$ 1,030	$ 603	$ 3,251	$ 1,884

Net Loss Per Share - Computatio

Net Loss Per Share - Computation of Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018
Earnings Per Share [Abstract]
Weighted average shares outstanding - basic and diluted (shares)	111,178,880			104,106,295			110,291,090	102,571,850
Net loss	$ (25,985)	$ (28,395)	$ (19,155)	$ (68,718)	$ 13,744	$ (15,816)	$ (73,535)	$ (70,792)
Net loss per share - basic and diluted ($ per share)	$ (0.23)			$ (0.66)			$ (0.67)	$ (0.69)

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Securities Excluded from Calculation of Net Loss Per Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive excluded from computation of earnings per share amount (shares)	2,747,040	9,123,874	3,310,223	9,597,648
Common stock options issued [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive excluded from computation of earnings per share amount (shares)	635,175	3,702,092	1,198,358	4,175,866
Restricted stock awards issued [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive excluded from computation of earnings per share amount (shares)	1,695,123	1,751,876	1,695,123	1,751,876
Restricted stock units issued [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive excluded from computation of earnings per share amount (shares)	385,919	245,214	385,919	245,214
Employee stock purchase plan shares pending issuance [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive excluded from computation of earnings per share amount (shares)	30,823	21,033	30,823	21,033
2013 Convertible Notes outstanding - if converted into common shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive excluded from computation of earnings per share amount (shares)	0	3,403,659	0	3,403,659

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Asset and Liability Fair Values (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Assets:
Equity securities (Note 7)	$ 33,559	$ 46,422
Restricted cash	4,040	0
Deferred compensation investments (life insurance cash surrender value (Note 3(e))	7,882	6,274
Total Assets	245,069	195,605
Liabilities:
Deferred compensation liability (Note 9(f))	7,848	6,167
Total Liabilities	7,848	6,167
Bank CDs [Member]
Assets:
Available-for-sale	6,152	86
Mutual Funds [Member]
Assets:
Available-for-sale	29	78
Money market funds [Member]
Assets:
Available-for-sale	89,041	142,745
US Government Debt Securities [Member]
Assets:
Available-for-sale	60,142
Corporate Debt Securities [Member]
Assets:
Available-for-sale	44,224
Level 1 [Member]
Assets:
Equity securities (Note 7)	33,559	46,422
Restricted cash	4,040
Deferred compensation investments (life insurance cash surrender value (Note 3(e))	0	0
Total Assets	164,088	46,422
Liabilities:
Deferred compensation liability (Note 9(f))	0	0
Total Liabilities	0	0
Level 1 [Member] | Bank CDs [Member]
Assets:
Available-for-sale	0	0
Level 1 [Member] | Mutual Funds [Member]
Assets:
Available-for-sale	0	0
Level 1 [Member] | Money market funds [Member]
Assets:
Available-for-sale	89,041	0
Level 1 [Member] | US Government Debt Securities [Member]
Assets:
Available-for-sale	37,448
Level 1 [Member] | Corporate Debt Securities [Member]
Assets:
Available-for-sale	0
Level 2 [Member]
Assets:
Equity securities (Note 7)	0	0
Restricted cash	0
Deferred compensation investments (life insurance cash surrender value (Note 3(e))	7,882	6,274
Total Assets	80,981	149,183
Liabilities:
Deferred compensation liability (Note 9(f))	7,848	6,167
Total Liabilities	7,848	6,167
Level 2 [Member] | Bank CDs [Member]
Assets:
Available-for-sale	6,152	86
Level 2 [Member] | Mutual Funds [Member]
Assets:
Available-for-sale	29	78
Level 2 [Member] | Money market funds [Member]
Assets:
Available-for-sale	0	142,745
Level 2 [Member] | US Government Debt Securities [Member]
Assets:
Available-for-sale	22,694
Level 2 [Member] | Corporate Debt Securities [Member]
Assets:
Available-for-sale	44,224
Level 3 [Member]
Assets:
Equity securities (Note 7)	0	0
Restricted cash	0
Deferred compensation investments (life insurance cash surrender value (Note 3(e))	0	0
Total Assets	0	0
Liabilities:
Deferred compensation liability (Note 9(f))	0	0
Total Liabilities	0	0
Level 3 [Member] | Bank CDs [Member]
Assets:
Available-for-sale	0	0
Level 3 [Member] | Mutual Funds [Member]
Assets:
Available-for-sale	0	0
Level 3 [Member] | Money market funds [Member]
Assets:
Available-for-sale	0	$ 0
Level 3 [Member] | US Government Debt Securities [Member]
Assets:
Available-for-sale	0
Level 3 [Member] | Corporate Debt Securities [Member]
Assets:
Available-for-sale	$ 0

Casi Holdings and Evomela Sup_2

Casi Holdings and Evomela Supply Contract - Additional Information (Details) $ in Thousands, shares in Millions	1 Months Ended	9 Months Ended		12 Months Ended
	Apr. 30, 2019USD ($)shares	Sep. 30, 2019USD ($)shares	Sep. 30, 2018USD ($)	Dec. 31, 2014agreement	Dec. 31, 2018USD ($)
Other Commitments [Line Items]
Equity securities		$ 33,559			$ 46,422
Gain (loss) on shares of common stock		$ 2,674	$ 0
CASI Out-License [Member]
Other Commitments [Line Items]
Number of agreements | agreement				3
Number of shares held in investment (shares) | shares		10
Percentage of ownership		10.40%
Equity securities		$ 33,600
Number of shares sold (shares) | shares	1.5
Gain (loss) on shares of common stock	$ 2,700

Convertible Senior Notes and _3

Convertible Senior Notes and Interest Expense - Additional Information (Details) - 2.75% Convertible Senior Notes Due 2018 [Member] - USD ($)	Dec. 15, 2018	Dec. 17, 2013	Dec. 31, 2017
Debt Disclosure [Line Items]
Sale of convertible notes, principal amount		$ 120,000,000
Interest rate		2.75%
Debt instrument, convertible, repurchased amount			$ 79,500,000
Conversion rate, shares (shares)	95
Conversion rate, price per share ($ per share)	$ 1,000

Convertible Senior Notes and _4

Convertible Senior Notes and Interest Expense - Components of the Interest Expense Recognized (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Debt Disclosure [Abstract]
Stated coupon interest expense	$ 246		$ 798
Amortization of debt issuance costs	56	$ 0	178
Accretion of debt discount	491	$ 0	1,558
Total interest expense	$ 793		$ 2,534
Effective interest rate	8.40%		8.40%

Financial Commitments & Conti_3

Financial Commitments & Contingencies and Key License Agreements - Additional Information (Details) $ in Thousands	1 Months Ended		3 Months Ended		9 Months Ended
	Apr. 30, 2019USD ($)product	Apr. 30, 2016shares	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Oct. 09, 2019USD ($)	Jan. 01, 2019USD ($)	Dec. 31, 2018USD ($)
Long-term Purchase Commitment [Line Items]
Operating lease right-of-use assets			$ 3,531		$ 3,531				$ 0
Operating lease liability			3,755		3,755
Lease cost			479	$ 500	1,584	$ 1,300
Lessee, operating lease, liability, payments due			4,204		4,204
Deferrals and contributions			$ 7,800		7,800				$ 6,200
SPI-2012 [Member]
Long-term Purchase Commitment [Line Items]
Issuance (shares) | shares		318,750
Potential payments based on achievement of regulatory milestones					10,000
Potential payments based on achievement of sales milestones					120,000
Poziotinib [Member] | Licensing Agreements [Member]
Long-term Purchase Commitment [Line Items]
Potential payments based on achievement of regulatory milestones					33,000
Potential payments based on achievement of sales milestones					325,000
MD Anderson [Member]
Long-term Purchase Commitment [Line Items]
Potential payments based on achievement of regulatory milestones					9,000
Potential payments based on achievement of sales milestones					$ 30,000
Accounting Standards Update 2016-02 [Member]
Long-term Purchase Commitment [Line Items]
Operating lease right-of-use assets								$ 4,200
Operating lease liability								$ 4,200
Minimum [Member]
Long-term Purchase Commitment [Line Items]
Lessee, operating lease, remaining lease term					1 year
Maximum [Member]
Long-term Purchase Commitment [Line Items]
Lessee, operating lease, remaining lease term					5 years
ImmunGene, Inc. [Member]
Long-term Purchase Commitment [Line Items]
Potential payments based on achievement of regulatory milestones					$ 26,100
Number of products | product	2
Asset purchase agreement, upfront payment	$ 2,800
Potential payments based on additional achievements of regulatory milestones					$ 5,000
Subsequent Event [Member]
Long-term Purchase Commitment [Line Items]
Lessee, operating lease, liability, payments due							$ 800

Financial Commitments & Conti_4

Financial Commitments & Contingencies and Key License Agreements - Operating Lease Balance Sheet Information (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Operating lease right-of-use assets	$ 3,531	$ 0
Operating lease current liabilities	326	0
Operating lease liabilities	3,429	$ 0
Total operating lease liabilities	$ 3,755

Financial Commitments & Conti_5

Financial Commitments & Contingencies and Key License Agreements - Components of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Operating lease cost	$ 351		$ 1,202
Short-term lease cost	108		323
Variable lease cost	20		59
Total lease cost	$ 479	$ 500	$ 1,584	$ 1,300

Financial Commitments & Conti_6

Financial Commitments & Contingencies and Key License Agreements - Summary of Operating Lease Term and Discount Rate (Details)	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Weighted Average Remaining Lease Term	3 years
Weighted Average Discount Rate	7.80%

Financial Commitments & Conti_7

Financial Commitments & Contingencies and Key License Agreements - Operating Lease Minimum Payments Due After Adoption of 842 (Details) $ in Thousands	Sep. 30, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
2019 (remaining)	$ 383
2020	1,441
2021	1,465
2022	828
2023	87
Total future lease payments, undiscounted	4,204
(Less): Implied interest	(449)
Present value of operating lease payments	$ 3,755

Financial Commitments & Conti_8

Financial Commitments & Contingencies and Key License Agreements - Operating Lease Minimum Payments Due Before Adoption of 842 (Details) $ in Thousands	Sep. 30, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
2019	$ 1,486
2020	1,441
2021	1,465
2022	828
2023 and thereafter	87
Total	$ 5,308

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Provision (benefit) for income taxes	$ (200)	$ (142)	$ (8,654)	$ (839)
Income tax expense (benefit) from discontinued operations	200	100	7,200	800
Income tax expense (benefit) from continuing and discontinued operations	$ (11)	$ 3	$ (1,500)	$ 8

Discontinued Operations - Finan

Discontinued Operations - Financial Results of Discontinued Operations (Details) - USD ($) $ in Thousands	Mar. 01, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Other (expense) income:
Provision for income taxes from discontinued operations		$ (200)	$ (100)	$ (7,200)	$ (800)
Income from discontinued operations, net of income taxes		572	454	21,625	2,659
Discontinued Operations, Disposed of by Sale [Member] | Commercial Product Portfolio [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total revenues		5,968	25,268	19,196	79,930
Operating costs and expenses:
Cost of sales (excluding amortization of intangible assets)		5,115	6,472	8,716	19,892
Selling, general and administrative		69	6,730	5,959	21,279
Research and development		(194)	5,745	2,597	15,167
Amortization of intangible assets		0	6,923	1,248	20,803
Restructuring charges - employee severance (Note 12)		0	0	3,858	0
Total operating costs and expenses		4,990	25,870	22,378	77,141
Income (loss) from discontinued operations		978	(602)	(3,182)	2,789
Other (expense) income:
Change in fair value of contingent consideration		0	1,200	(1,478)	717
Gain on sale of Commercial Product Portfolio		(193)	0	33,451	0
Total other (expense) income		(193)	1,200	31,973	717
Income from discontinued operations before income taxes		785	598	28,791	3,506
Provision for income taxes from discontinued operations		(213)	(144)	(7,166)	(847)
Income from discontinued operations, net of income taxes		572	454	21,625	2,659
Proceeds from sale of discontinued operations	$ 158,800
Carrying value of net assets transferred	121,200
Transaction expenses	3,900
Contract termination fee		200
Escrow deposits	$ 4,000	4,000		4,000
Discontinued Operations, Disposed of by Sale [Member] | Commercial Product Portfolio [Member] | Product [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total revenues		5,968	24,556	18,906	76,419
Discontinued Operations, Disposed of by Sale [Member] | Commercial Product Portfolio [Member] | License and Service [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total revenues		$ 0	$ 712	$ 290	$ 3,511

Discontinued Operations - Summa

Discontinued Operations - Summary of Assets and Liabilities of Discontinued Operations (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued operations, current assets	$ 0	$ 5,555
Discontinued operations, non-current assets	0	132,625
Discontinued operations, current liabilities	0	2,311
Discontinued operations, non-current liabilities	$ 0	14,031
Discontinued Operations, Disposed of by Sale [Member] | Commercial Product Portfolio [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Inventories		3,550
Prepaid expenses and other assets		2,005
Discontinued operations, current assets		5,555
Intangible assets, net of accumulated amortization		111,594
Goodwill		18,061
Other assets		2,970
Discontinued operations, non-current assets		132,625
FOLOTYN development liability		2,311
Discontinued operations, current liabilities		2,311
FOLOTYN development liability, less current portion		9,686
Acquisition-related contingent obligations		4,345
Discontinued operations, non-current liabilities		$ 14,031

Discontinued Operations - Signi

Discontinued Operations - Significant Non-cash Supplemental Cash Flow Items of Discontinued Operations (Details) - Commercial Product Portfolio [Member] - Discontinued Operations, Disposed of by Sale [Member] - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation and amortization	$ 1,263	$ 20,871
Stock-based compensation	3,404	4,626
Change in fair value of contingent consideration	$ 1,478	$ (655)

Restructuring Costs Related T_2

Restructuring Costs Related To Sale Of Commercial Product Portfolio (Details) $ in Thousands	Mar. 01, 2019employee	Sep. 30, 2019USD ($)	May 31, 2019USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)
Restructuring Cost and Reserve [Line Items]
Number of employees terminated or given notice of termination | employee	87
Revenue from contract with customer		$ 0		$ 0	$ 0	$ 0
Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs expected cost remaining		400			400
Employee Severance, Terminated March 1, 2019 [Member] | Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs					5,100
Employee Severance, Terminated March 1, 2019 [Member] | Employee Severance [Member] | Income (Loss) From Discontinued Operations [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs					3,900
Employee Severance, Terminated March 1, 2019 [Member] | Employee Severance [Member] | Selling, general and administrative [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs					1,000
Employee Severance, Terminated March 1, 2019 [Member] | Employee Severance [Member] | Research and development [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs					200
Employee Severance, Terminated May 31, 2019 [Member] | Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs		0	$ 500		500
Acrotech Biopharma LLC [Member] | Service [Member]
Restructuring Cost and Reserve [Line Items]
Revenue from contract with customer		$ 0			$ 700

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)	Apr. 05, 2019	Sep. 30, 2019	Sep. 30, 2019	Sep. 30, 2019	Sep. 30, 2018
Equity [Abstract]
Maximum proceeds	$ 150,000,000
Proceeds Received (Net of Broker Commissions and Fees )		$ 0	$ 1,814,000	$ 1,817,000	$ 0
Common stock issued (shares)			221,529

Uncategorized Items - sppi20190

Label	Element	Value
Cumulative Effect Of Foreign Currency Adjustment Due To New Accounting Adoption	sppi_CumulativeEffectOfForeignCurrencyAdjustmentDueToNewAccountingAdoption	$ 342,000
Retained Earnings [Member]
Cumulative Effect Of Foreign Currency Adjustment Due To New Accounting Adoption	sppi_CumulativeEffectOfForeignCurrencyAdjustmentDueToNewAccountingAdoption	342,000
Accounting Standards Update 2014-09 [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	4,678,000
Accounting Standards Update 2014-09 [Member] | Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 4,678,000